Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT00065962	Secretin for the Treatment of Autism		Completed	No Results Available	Autism	Drug: secretin, synthetic porcine|Drug: secretin, biologically derived porcine		Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	3 Years to 12 Years   (Child)	Phase 3	85	NIH	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment	5P01HD035465|NICHD-23|57-937|Supplement CRC99-3|3P01HD035468	June 1999		May 2000	August 5, 2003		June 24, 2005	Children's Hospital, Denver, Colorado, United States|Center on Human Development and Disability, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00065962
2	NCT00065910	Improving Attention Skills of Children With Autism		Completed	No Results Available	Autism	Behavioral: Caregiver joint attention intervention		Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)	All	12 Months to 36 Months   (Child)	Phase 1|Phase 2	30	NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R21MH064927	September 2001		January 2006	August 5, 2003		July 2, 2007	University of California, Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00065910
3	NCT00065884	Valproate Response in Aggressive Autistic Adolescents		Unknown status	No Results Available	Autism	Drug: Valproate		Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)	All	6 Years to 21 Years   (Child, Adult)	Phase 3	30	NIH	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment	P30HD002528|K08MH001516				August 5, 2003		June 24, 2005	Outpatient MR/Autism Clinic, University of Kansas, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT00065884
4	NCT01887132	A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism		Terminated	Has Results	Autism Spectrum Disorders	Drug: Donepezil|Drug: Placebo	Nonverbal Developmental Quotient (NVDQ)|REM Percentage at Baseline, 6, 12 and 18 Months	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	24 Months to 50 Months   (Child)	Phase 2	5	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	130164|13-M-0164	June 2013	December 2015	December 2015	June 26, 2013	September 25, 2017	September 25, 2017	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT01887132
5	NCT01168284	A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum: A Feasibility Study		Completed	No Results Available	Autism Spectrum Disorders	Behavioral: Coping Effectiveness Training	Feasibility of the intervention	National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	30	NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Other	999910160|10-HG-N160	July 5, 2010	April 4, 2011	May 6, 2011	July 23, 2010		December 17, 2019	Kennedy Krieger Institute, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01168284
6	NCT00999778	Optimizing Social and Communication Outcomes for Toddlers With Autism		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Caregiver-Mediated Intervention|Behavioral: Caregiver-Education Intervention	Cognitive Assessment - Mullen Scales of Early Learning (MSEL)|Language Assessment - Reynell Developmental Language Scales|Language Sample - The Caregiver Child Interaction will be coded at each timepoint to obtain a 10 minute sample of the child's language transcription will yield a measure of lexical density, type-token ration and mean length of utterances|Early Social-Communication Scales; frequencies of initiating and responses of joint attention behaviors to toys and l interaction - sessions will be video taped|MacArthur Communicative Development Inventories|Parent Expectancy/Belief in the Intervention - assesses caregiver beliefs that the intervention is appropriate and working for the child|ADOS - The Autism Diagnostic Observation Schedule - semi-structured, standardized assessment of communication, social interaction, play and imaginative use of materials|Generalization of skills to classroom - Observational measure to determine whether child show generalization of skill to the classroom,and in interaction with teachers & peers|Coding of child behaviors in classroom - using time sampling procedure, four different contexts; direct instruction, structure play, circle-time, unstructured play|Caregiver-child interaction - A 10-minute interaction between parent and child|ADI-R Clinical diagnostic instrument for assessing autism in children|Parenting Stress - The Parenting Stress Index (PSI) measuring parents reported stress associated with the care of autistic child	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Autism Speaks	All	18 Months to 36 Months   (Child)	Not Applicable	86	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	1P50HD055784	July 2008	July 2012	August 2012	October 22, 2009		August 16, 2012	University of California Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00999778
7	NCT04798274	Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder		Recruiting	No Results Available	Autism Spectrum Disorder	Device: Continuous Theta Burst Stimulation	MRS|MEG|fcMRI|DTI|Neuropsychological Assessments	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	14 Years to 25 Years   (Child, Adult)	Not Applicable	106	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	200159|20-M-0159	June 15, 2021	June 30, 2024	June 30, 2024	March 15, 2021		August 22, 2022	National Institutes of Health Clinical Center, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT04798274
8	NCT01093768	Brain Imaging Study of Adults With Autism Spectrum Disorders		Completed	No Results Available	Autism Spectrum Disorders	Drug: Oxytocin|Drug: Vasopressin	Changes in brain activations|Performance scores and reaction time on behavioral tasks	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	18 Years to 40 Years   (Adult)	Phase 1	38	NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Diagnostic	100068|10-M-0068	February 19, 2010	April 11, 2013	April 11, 2013	March 26, 2010		December 17, 2019	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT01093768
9	NCT02998684	Learning Enhancement Through Neurostimulation in Autism	LENS	Completed	Has Results	Autism	Device: Active Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation|Behavioral: PEERS Social Skills Training	Test of Adolescent Social Skills Knowledge (TASSK)|Social Responsiveness Scale (SRS)	Medical University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	14 Years to 17 Years   (Child)	Not Applicable	25	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Pro00056912	July 2016	July 2017	July 2017	December 20, 2016	September 4, 2018	September 4, 2018	Medical Univeristy of South Carolina, Charleston, South Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02998684/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02998684
10	NCT00409747	Minocycline to Treat Childhood Regressive Autism		Completed	Has Results	Autism|Minocycline|Regressive Autism	Drug: Minocycline	z Score|Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	3 Years to 12 Years   (Child)	Phase 4	11	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	070024|07-M-0024	November 2006	June 2010	April 2011	December 11, 2006	December 11, 2015	December 11, 2015	Childrens National Medical Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00409747
11	NCT00695136	The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism		Completed	Has Results	Autism|Cognition Disorder	Drug: Donepezil hydrochloride|Behavioral: Increase REM sleep percentage	Change in Percentage of Time That Subjects With Autism Spend in REM Sleep.	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	2 Years to 10 Years   (Child)	Phase 1|Phase 2	17	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	080154|08-M-0154	June 2008	January 2011	January 2011	June 11, 2008	April 24, 2013	April 24, 2013	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00695136
12	NCT00005014	Treatment of Autism in Children and Adolescents		Completed	No Results Available	Autistic Disorder	Drug: Risperidone		National Institute of Mental Health (NIMH)	All	5 Years to 17 Years   (Child)	Phase 3	101	NIH	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	N01 MH70001|N01 MH70009|N01 MH80011|N01 MH70010|DSIR CT	October 1997		February 2001	April 3, 2000		April 17, 2014	UCLA, Los Angeles, California, United States|Yale Univ, New Haven, Connecticut, United States|Indiana Univ / Riley Hosp for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State Univ, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00005014
13	NCT03152383	Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism		Completed	No Results Available	Autism	Behavioral: Training trials|Behavioral: Progressive Ratio Session|Behavioral: Re-test|Behavioral: Pairing Protocol	Breakpoint achieved for each stimulus|Change in breakpoints	Emory University|National Institute of Mental Health (NIMH)	All	2 Years to 6 Years   (Child)	Not Applicable	64	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00056563|R21MH108873	June 22, 2012	December 31, 2020	December 31, 2020	May 15, 2017		March 1, 2021	Marcus Autism Center, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03152383
14	NCT05540574	Trial of Zolpidem for Sleep in Children With Autism		Not yet recruiting	No Results Available	Autism|Autism Spectrum Disorder	Drug: Zolpidem|Drug: Placebo	Change from baseline in sleep architecture as measured by polysomnography (PSG), examples include sleep latency and non-rapid eye movement (NREM)|Change from baseline in sleep efficiency as measured by actigraphy	Stanford University|National Institutes of Health (NIH)	All	8 Years to 17 Years   (Child)	Phase 2	26	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	IRB-67221	January 1, 2023	June 30, 2027	June 30, 2027	September 14, 2022		November 30, 2022			https://ClinicalTrials.gov/show/NCT05540574
15	NCT05546554	Trial of Suvorexant for Sleep in Children With Autism		Not yet recruiting	No Results Available	Autism|Autism Spectrum Disorder	Drug: Suvorexant|Drug: Placebo	Change from baseline in sleep architecture as measured by polysomnography (PSG), examples include sleep latency and non-rapid eye movement (NREM)|Change from baseline in sleep efficiency as measured by actigraphy	Stanford University|National Institutes of Health (NIH)	All	13 Years to 17 Years   (Child)	Phase 2	26	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	IRB-67222	January 1, 2023	June 30, 2027	June 30, 2027	September 21, 2022		November 30, 2022			https://ClinicalTrials.gov/show/NCT05546554
16	NCT00498173	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism		Completed	Has Results	Autism	Drug: Atomoxetine|Drug: Placebo	ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase)|ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Randomized Phase)|Aberrant Behavior Checklist (ABC) (Randomized Phase)|Social Responsiveness Scale (SRS) (Randomized Phase)|Vineland Adaptive Behavior Scales (VABS) Composite Score (Randomized Phase)|Pediatric Quality of Life Inventory (Randomized Phase)|Pediatric Anxiety Rating Scale, 5-Item Total (Randomized Phase)|Odds of Clinical Global Impression-Improvement Scale, Very Much or Much Improved (1 or 2) (Randomized Phase)|Change in ADHD Rating Scale (ADHDRS)-Home Version Total Score (Open-label Trial)|Change in ADHD Rating Scale (ADHDRS)-Home Version Inattention and Hyperactivity Scores (Open-label Trial)|Change in Aberrant Behavior Checklist (ABC) (Open-label Trial)|Change in Social Responsiveness Scale (SRS) (Open-label Trial)|Change in Vineland Adaptive Behavior Scales (VABS) Composite Score (Open-label Trial)|Change in Pediatric Quality of Life Inventory (Open-label Trial)|Change in Pediatric Anxiety Rating Scale, 5-item Total (Open-label Trial)	Massachusetts General Hospital|National Institute of Mental Health (NIMH)	All	5 Years to 15 Years   (Child)	Phase 3	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	R01MH077600|DDTR B2-NDA	July 2007	October 2015	October 2015	July 9, 2007	August 14, 2017	August 14, 2017	Christian Sarkine Autism Treatment Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Lurie Center - MassGeneral Hospital, Lexington, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00498173
17	NCT05501678	Trial of Diphenhydramine for Sleep in Children With Autism		Not yet recruiting	No Results Available	Autism|Autism Spectrum Disorder	Drug: Diphenhydramine|Drug: Placebo	Change from baseline in sleep latency as measured by polysomnography (PSG)|Change from baseline in duration of non-rapid eye movement (NREM) sleep as measured by polysomnography (PSG)|Change from baseline in sleep efficiency as measured by polysomnography (PSG) and actigraphy	Stanford University|National Institutes of Health (NIH)	All	8 Years to 17 Years   (Child)	Phase 2	26	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	IRB-66941	January 1, 2023	June 30, 2027	June 30, 2027	August 15, 2022		November 30, 2022			https://ClinicalTrials.gov/show/NCT05501678
18	NCT02037022	Pivotal Response Treatment Package for Young Children With Autism	PRT-P	Completed	No Results Available	Autism Spectrum Disorder (ASD)|Autism	Behavioral: Pivotal Response Treatment Package (PRT-P)	Change from Baseline in communication during parent-child and clinician-child interactions at 6, 12, and 24 weeks|Change from Baseline on the Preschool Language Scale, 5th Edition (PLS-5) at 12, and 24 weeks|Change from Baseline on the Sensory Profile Questionnaire at 6, 12, and 24 weeks|Change from Baseline on the Social Responsiveness Scale (SRS) at 6, 12, and 24 weeks|Change from Baseline on the MacArthur-Bates Communication Development Inventory at 6, 12, and 24 weeks|Change from Baseline on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) at 6, 12, and 24 weeks|Change from Baseline on the Behavior Rating Inventory of Executive Function, Preschool (BRIEF-P) at 6, 12, and 24 weeks|Change from Baseline on the Parenting Stress Index (PSI) at 6, 12, and 24 weeks|Change from Baseline on the Family Empowerment Scale (FES) at 6, 12, and 24 weeks|Change from Baseline on the Clinical Global Impression Scale at 6, 12, and 24 weeks|Change from Baseline on the Social attention and word-learning eye tracking task at 12, and 24 weeks	Stanford University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	2 Years to 5 Years   (Child)	Not Applicable	48	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-28314|R21DC013689	December 4, 2013	July 28, 2017	July 28, 2017	January 15, 2014		February 25, 2020	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT02037022
19	NCT04349644	Enhancing Social Competence in Adults With Autism		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: SENSE Theatre	Change in Incidental Face Memory|Change in Contextual Assessment of Social Skills|Change in Social Responsiveness Scale - Self (SRS)|Change in Social Responsiveness Scale - Parent (SRS)|Cambridge Face Memory Test|Wechsler Memory Scale Face Memory Delay Test|Wechsler Memory Scale Face Memory Test|Adaptive Behavior Assessment System (ABAS) - Self-Report|Adaptive Behavior Assessment System (ABAS) - Parent-Report|State-Trait Anxiety Inventory (STAI) Scale|The Adult Self Report (ASR)|The Adult Behavior Checklist (ABCL)	Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)	All	18 Years to 35 Years   (Adult)	Not Applicable	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	192271|1R33MH120149-01A1	October 21, 2020	April 1, 2023	April 1, 2023	April 16, 2020		February 21, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04349644/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04349644
20	NCT02632773	Parent Language Intervention for Autism		Completed	No Results Available	Autism	Behavioral: Responsive Intervention|Behavioral: Directive Intervention	Parent Use of Language Support Strategies (Mother-child interaction)|Expressive vocabulary of the child as measured by transcribing and coding a 20 minute video of a therapist-child interaction in the clinic with a standard set of age-appropriate toys.|MacArthur-Bates Communicative Development Inventory (MCDI) (Child)	Northwestern University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	18 Months to 48 Months   (Child)	Not Applicable	108	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	1R01DC014709-01	August 2015	March 2020	March 2020	December 17, 2015		July 16, 2021	Northwestern University, Evanston, Illinois, United States		https://ClinicalTrials.gov/show/NCT02632773
21	NCT02968225	Using Serious Game Technology to Improve Sensitivity to Eye Gaze in Autism	SAGA	Completed	No Results Available	Autism	Behavioral: Computer Game	Static Eye Gaze Following Task|Dynamic Eye Gaze Following Task|Social/Visual Attention Task|Social Responsiveness Scale|Social Skills Inventory System - Child version|Social Skills Inventory System - Adult version|Treatment as Usual	Penn State University|National Institute of Mental Health (NIMH)	All	10 Years to 18 Years   (Child, Adult)	Phase 2	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	R61MH110624	August 2016	October 2018	October 2018	November 18, 2016		March 5, 2021	Pennsylvania State University, University Park, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02968225
22	NCT01944046	Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors	SOARS-B	Completed	Has Results	Autism Spectrum Disorders	Drug: Double blind phase Placebo Nasal Spray|Drug: double Blind Oxytocin Nasal Spray|Drug: Open Label intranasal oxytocin	Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity|Change in Sociability Factor (SF)|Change in Social Responsiveness Scale-2 (SRS-2) Social Motivation Subscale Score|Change in Stanford Binet-5th Edition (SB-5) IQ Score	Linmarie Sikich|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University	All	3 Years to 17 Years   (Child)	Phase 2	290	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Pro00063950|1U01HD073984|13-0593	August 1, 2014	November 30, 2017	November 30, 2017	September 17, 2013	January 5, 2021	June 18, 2021	Lurie Center for Autism, Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai School of Medicine, New York, New York, United States|Center for Autism and the Developing Brain, White Plains, New York, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Duke University , Genetics Center, Durham, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Seattle Children's Hospital Research Institute, Seattle, Washington, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01944046/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01944046
23	NCT04283045	Community-based Adaptive Autism Intervention for Toddlers	CAIT	Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: JASPER|Behavioral: JASPER Plus+	Change in social communicative utterances (SCU) using Short Play and Communication Evaluation (SPACE)|Change in social communicative utterances (SCU) using JASPER Deployment Project Treatment Fidelity Checklist (TCX)|Change in play levels/types using the Short Play and Communication Evaluation (SPACE)|Change in joint engagement using the JASPER Deployment Project Treatment Fidelity Checklist (TCX)	University of California, Los Angeles|National Institutes of Health (NIH)	All	24 Months to 36 Months   (Child)	Not Applicable	350	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-000197	December 3, 2020	August 29, 2025	December 19, 2025	February 25, 2020		January 21, 2022	New York Center for Infants and Toddlers, Inc., New York, New York, United States		https://ClinicalTrials.gov/show/NCT04283045
24	NCT05300295	Mentorship Program for Individuals With Autism Spectrum Disorder (ASD)		Completed	Has Results	Autism Spectrum Disorder	Behavioral: Mentoring Program	Number of Sessions Attended|Participant Program Satisfaction Scores|Mentoring Relationship Quality|Child Behavior Checklist Scores (Internalizing Subscale)|Child Behavior Checklist Scores (Externalizing Subscale)|Youth Self-Report Scores (Internalizing Subscale)|Youth Self-Report Scores (Externalizing Subscale)|Social Skills Improvement System Scores (Social Competence Scale; Parent-report)|Social Skills Improvement System Scores (Problem Behavior Scale; Parent-report)|Social Skills Improvement System Scores (Social Competence Scale; Youth-report)|Social Skills Improvement System Scores (Problem Behavior Scale; Youth-report)	University of Minnesota|National Institutes of Health (NIH)	All	14 Years and older   (Child, Adult, Older Adult)	Not Applicable	13	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	STUDY00003954	January 1, 2019	May 31, 2020	May 31, 2020	March 29, 2022	October 21, 2022	October 21, 2022	University of Minnesota, Minneapolis, Minnesota, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/95/NCT05300295/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/95/NCT05300295/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT05300295
25	NCT00211757	Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism		Completed	Has Results	Autism	Drug: Divalproex sodium|Drug: Placebo	Number of Participants Reporting Improvement on the Clinical Global Impression|Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores	Montefiore Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)	All	5 Years to 17 Years   (Child)	Phase 2	27	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	01-0294|1R21NS043979	September 2002	July 2008	July 2008	September 21, 2005	December 6, 2018	December 6, 2018	Mount Sinai School of Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00211757
26	NCT03033784	Autism Oxytocin Brain Project		Completed	Has Results	Autism|Autism Spectrum Disorder	Drug: 8 International Units (IU) of Oxytocin|Drug: 24IU of Oxytocin|Drug: 48IU of Oxytocin|Drug: Placebo	Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex)|Blood Oxygen Level Dependent (BOLD) Activity in Response to Social Cues|Percent Change in Blood Oxygen Level Dependent (BOLD) Activity During Ball-Game Task|Oxytocin Plasma Concentration|Rate of Smiling During Global Clinical Interview|Milliseconds of Visual Fixation|Social Learning Test (SLT) Reaction Time	Emory University|National Institute of Mental Health (NIMH)	Male	18 Years to 45 Years   (Adult)	Phase 2	51	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB00093455|P50MH100023	May 10, 2017	October 3, 2018	October 3, 2018	January 27, 2017	January 12, 2021	January 12, 2021	Emory University, Atlanta, Georgia, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/Prot_SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03033784/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT03033784
27	NCT01018407	Interventions for Communication in Autism Network	ICAN	Completed	No Results Available	Autism	Behavioral: Discrete Trial Training|Behavioral: Interpersonal Developmental Approach	Reynell Developmental Language Scale|McArthur-Bates Communicative Development Inventory (Word and Gestures Inventory and/or Words and Sentences Inventory)|Caregiver-child Interaction|Early Social Communication Scale|Structured Play Assessment	University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	33 Months to 54 Months   (Child)	Not Applicable	192	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1R01MH084864-01A109|1R01MH084864|DDTR B2-MBA	December 2009	June 2015	June 2015	November 23, 2009		June 8, 2015	University of California, Los Angeles, Los Angeles, California, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Rochester, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT01018407
28	NCT03690661	Using Serious Games to Improve Social Skills in Autism	SAGA	Recruiting	No Results Available	Autism Spectrum Disorder|Autism	Behavioral: Intervention Video Game|Behavioral: Placebo Control Game	Primary Target Eye Gaze Mechanisms - Performance Accuracy|Primary Target Eye Gaze Mechanisms - Visual Fixation|Social Symptoms - Social Skills Inventory System (SSIS)|Autism Behaviors - Social Responsiveness Scale 2nd Edition (SRS-2)|Intermediate Face Processing Mechanisms - Face Identity (CFMT)|Intermediate Face Processing Mechanisms - Object Identity (CBMT)|Intermediate Face Processing Mechanisms - Face Expression Identification - (CAM)|Intermediate Face Processing Mechanisms - Face Expression Identification - (RMET)|Face-to-Face Social Interactions - Visual Fixations	Penn State University|National Institute of Mental Health (NIMH)	All	10 Years to 18 Years   (Child, Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	R33MH110624	December 1, 2019	July 31, 2023	July 31, 2023	October 1, 2018		July 7, 2022	Pennsylvania State University, University Park, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03690661
29	NCT05494398	Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label		Enrolling by invitation	No Results Available	Autism Spectrum Disorder	Drug: N-acetylcysteine	Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)|Change in restricted and repetitive behaviors as measured by Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder (CYBOCS-ASD)|Change in Gamma band amplitude and synchronization measured by electroencephalography (EEG)|Change in restricted repetitive behavior subtypes as measured by the Restricted Behavior Scale - Revised (RBS-R)	Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	3 Years to 12 Years   (Child)	Phase 2|Phase 3	48	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-64292|K99HD101702	November 15, 2022	September 2027	September 2028	August 10, 2022		December 9, 2022	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT05494398
30	NCT03583684	Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism	PRT-I	Recruiting	No Results Available	Autism Spectrum Disorder|Autism	Behavioral: Pivotal Response Treatment Program (PRT-P)	Change in Number of Child Utterances During a Structured Lab Observation (SLO)|Change on MacArthur-Bates Communication Development Inventory (CDI)	Stanford University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	2 Years to 4 Years   (Child)	Not Applicable	36	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	IRB-46131	December 7, 2018	November 30, 2024	November 30, 2024	July 11, 2018		February 16, 2022	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT03583684
31	NCT00183404	Long-Term Olanzapine Treatment in Children With Autism		Completed	No Results Available	Autism	Drug: Olanzapine	Children's Psychiatric Rating Scale|Aberrant Behavior Checklist|Clinical Global Impressions|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale	Drexel University|National Institute of Mental Health (NIMH)	All	3 Years to 12 Years   (Child)	Phase 2|Phase 3	32	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R01MH073524|DDTR B2-NDA	September 2004	July 2011	October 2011	September 16, 2005		August 15, 2014	Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00183404
32	NCT01529580	School-Age Children With Autism With Limited Expressive Language Skills		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Non-Verbal School Aged Children with Autism (NVSACA) Intervention	Change in Baseline Spontaneous Language|Change in Baseline Autism Diagnostic Observation Schedule|Change in Baseline Reynell|Changes in Baseline Early Social Communication Scales (ESCS)|Changes in Baseline Structured Play Assessment	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute of Mental Health (NIMH)	All	48 Months to 95 Months   (Child)	Not Applicable	13	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NA_00049467|3R01MH085048-03S1	January 2012	December 2013	December 2013	February 9, 2012		March 10, 2021	Kennedy Krieger Institute, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01529580
33	NCT04278898	Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose		Recruiting	No Results Available	Autism Spectrum Disorder	Drug: N-Acetylcysteine	Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)|Change in Gamma band amplitude and synchronization measured by electroencephalography	Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	3 Years to 12 Years   (Child)	Phase 2	24	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB-54931	February 12, 2021	August 2023	January 2024	February 20, 2020		September 8, 2022	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT04278898
34	NCT00090428	Diet and Behavior in Young Children With Autism		Completed	No Results Available	Autism|Autistic Disorder	Behavioral: Gluten- and casein-free diet|Behavioral: Placebo controlled diet	Safety and efficacy of the gluten free casein free diet	University of Rochester|National Institute of Mental Health (NIMH)	All	30 Months to 54 Months   (Child)	Phase 1	21	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	U54MH066397|DDTR BD-DD	January 2004	October 2008	February 2009	August 27, 2004		February 1, 2013	University of Rochester Medical Center, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT00090428
35	NCT01170325	A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG		Withdrawn	No Results Available	Autism|Autism Spectrum Disorders	Drug: Divalproex Sodium|Drug: Placebo Comparator	epileptiform EEG discharges|Improvement in behavior	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	3 Years to 10 Years   (Child)	Phase 2	0	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	100157|10-M-0157	June 30, 2010	January 28, 2011	January 28, 2011	July 27, 2010		July 2, 2017	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT01170325
36	NCT03204786	Intranasal Vasopressin Treatment in Children With Autism		Recruiting	No Results Available	Autism|Autism Spectrum Disorder|ASD	Drug: Vasopressin (USP) Injectable Solution [Vasostrict]|Drug: Placebo	Change from baseline in parent rated Social Responsiveness Scale, Second Edition Total Scores (SRS-2) total scores during treatment.|Change from baseline in Clinical Global Impression (CGI) scores during treatment.|Change from baseline on Reading the Mind in the Eyes Test (RMET) during treatment.|Change from baseline on the Facial Emotion Recognition Test during treatment.|Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.|Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.|Change from baseline on electrocardiogram (EKG) (P Duration, PR Interval, QRS Interval, QT Interval) during treatment.|Change from baseline on clinical labs (Sodium, Potassium, Chloride) during treatment.|Change from baseline on blood pressure (systolic and diastolic) during treatment.|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) during treatment.|Change from baseline in Overt Aggression Scale (OAS) during treatment.|Baseline vasopressin concentration predicting primary and secondary behavioral outcome measures.	Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	6 Years to 17 Years   (Child)	Phase 2|Phase 3	100	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB-39972|1R01HD091972	February 20, 2018	April 1, 2024	July 1, 2024	July 2, 2017		September 15, 2022	Stanford University, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT03204786
37	NCT03556826	Social Value Training in Toddlers With Elevated Autism Symptoms	SVT	Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Social Value Learning Training	Proportion of looking at faces during the laboratory and real-world tests|Proportion of looking at the scene during laboratory and real-world tests	Yale University|National Institute of Mental Health (NIMH)	All	15 Months to 21 Months   (Child)	Not Applicable	48	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000021541|P50MH115716	December 13, 2019	August 31, 2023	August 31, 2024	June 14, 2018		July 15, 2022	Yale University School of Medicine, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03556826
38	NCT01171937	Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior	ProjectV	Completed	No Results Available	Autism	Drug: Risperidone|Drug: Placebo	Aberrant Behavior Checklist	University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	8 Years to 16 Years   (Child)	Phase 2	41	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	07-06-033|P50HD055784	September 2008	September 2016	December 2016	July 29, 2010		May 17, 2022	UCLA, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT01171937
39	NCT00467818	Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders		Completed	Has Results	Autism	Drug: Omega 3 fatty acids|Other: Placebo	Clinical Global Impression Scale(CGI)- Improvement|Aberrant Behavior Checklist (ABC)|Vineland Adaptive Behavior Scale|Overt Aggression Scale-Modified|Parental Stress Index	University of Medicine and Dentistry of New Jersey|National Center for Complementary and Integrative Health (NCCIH)|Rutgers, The State University of New Jersey	All	5 Years to 17 Years   (Child)	Not Applicable	17	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	0220060238|5R21AT002927	January 2007	December 2010	December 2010	May 1, 2007	December 16, 2020	January 26, 2021	University Behavioral Health Care Building, UMDNJ-RWJMS, Piscataway, New Jersey, United States		https://ClinicalTrials.gov/show/NCT00467818
40	NCT01962870	The Role of Vasopressin in the Social Deficits of Autism		Completed	Has Results	Autism Spectrum Disorders	Drug: Vasopressin|Drug: Placebo	Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.|Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment.|Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.|Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.|Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.|Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.|Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment|Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.|Change From Baseline in Heart Rate After Treatment.|Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment.|Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment.|Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment.|Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment.|Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.|Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.|Change From Baseline in Blood Pressure After Treatment|Change From Baseline in Body Weight After Treatment.|Change From Baseline in Body Temperature After Treatment|Change From Baseline in the Awareness of Social Inference Test Revised (TASIT-R) Scores During Treatment.|Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment.|Change From Baseline in Plasma Vasopressin Levels During Treatment.	Stanford University|National Institute of Mental Health (NIMH)	All	6 Years to 12 Years   (Child)	Phase 2	68	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IRB-26034|R21MH100387-01	December 2013	May 30, 2017	May 30, 2017	October 14, 2013	May 24, 2019	May 24, 2019	Stanford University School of Medicine; Psychiatry and Behavioral Sciences, Stanford, California, United States	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/70/NCT01962870/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT01962870
41	NCT00095420	Relationship Training for Children With Autism and Their Peers		Completed	No Results Available	Autism|Autistic Disorder	Behavioral: Social skills training targeting children with autism|Behavioral: Social skills training of peers without autism|Behavioral: Combination treatment of social skills/education about autism|Behavioral: Usual training	Social network involvement of autistic children	University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	6 Years to 11 Years   (Child)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	U54MH068172|DDTR BD-DD	September 2003	June 2008	June 2008	November 5, 2004		February 25, 2022	University of California, Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00095420
42	NCT01322022	Treatment of Sleep Disturbances in Young Children With Autism		Completed	Has Results	Autism|Autism Spectrum Disorders	Behavioral: ParentTraining|Other: Parent Education	Modified Simond & Parraga Sleep Questionnaire (MSPSQ) - Composite Sleep Index|Actigraphy - Sleep Efficiency|Actigraphy - Sleep Latency|Actigraphy - Total Sleep Time	University of Pittsburgh|National Institute of Mental Health (NIMH)	All	24 Months to 72 Months   (Child)	Not Applicable	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO09070340|R34MH082882	December 2009	November 2012	January 2013	March 24, 2011	February 2, 2015	August 25, 2015	Children's Hospital of Pittsburgh Autism Cetner, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01322022
43	NCT00106210	School- and Home-Based Early Intervention for Toddlers With Autism		Completed	No Results Available	Autistic Disorder|Autism	Behavioral: Early intervention blending several tx approaches, w/ focus|Behavioral: Early intervention blending several treatment approaches	Receptive language skills|Expressive language skills|Social cognitive skills|Social emotional functioning|Play skills	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute of Mental Health (NIMH)	All	18 Months to 33 Months   (Child)	Not Applicable	50	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	U54MH066417|DDTR BD-DD	May 2003	September 2007	September 2007	March 22, 2005		July 8, 2013	Kennedy Krieger Institute, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT00106210
44	NCT03606343	Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting	TASK-R21	Completed	Has Results	Autism Spectrum Disorder	Behavioral: Teaching Academic Skills to Kids	Children's Organizational Skills Scale|Behavior Rating Inventory of Executive Function - Second Edition|Homework Problem Checklist|Woodcock Johnson Tests of Achievement - Third Edition Basic Writing Subtest|Classroom Performance Survey|Academic Performance Rating System|Parenting Relationship Questionnaire - Communication Subscale	Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	11 Years to 14 Years   (Child)	Not Applicable	21	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R21HD090334-01A1	September 1, 2017	August 31, 2020	August 31, 2020	July 30, 2018	November 24, 2020	December 17, 2020	Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03606343/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03606343
45	NCT00609531	Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders		Completed	No Results Available	Autism Spectrum Disorders	Drug: Citalopram|Drug: Placebo	Functional Magnetic Resonance Imaging|Clinicians Global Improvement Scale|Childrens Yale-Brown Obsessive Compulsive Scale	University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)	All	10 Years to 55 Years   (Child, Adult)	Phase 1	12	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)	04-0975|NIH/NCRR K12 RR023248|The Dana Foundation|K23MH081285	January 2007	August 2009	August 2009	February 7, 2008		October 8, 2012	UNC-Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00609531
46	NCT03873831	Effects of Therapy Dogs on Social Behavior in Group Social Skills Instruction With Children With Autism		Unknown status	No Results Available	Autism Spectrum Disorder|Social Skills	Behavioral: Animal-assisted intervention|Behavioral: Social skills group	Verbal utterances|Direction of utterances|Quality of utterance|Unwanted behavior|Social behavior|Heart Rate|Electrodermal activity|Salivary cortisol|Quality of instruction: correct and timely feedback|Quality of instruction: adherence to the program script|Quality of instruction: attention to children	Texas Tech University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	11 Years to 17 Years   (Child)	Not Applicable	72	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Therapy Dogs Group Autism|R21HD095206	May 15, 2019	December 31, 2020	December 31, 2020	March 14, 2019		September 6, 2019	Texas Tech University, Lubbock, Texas, United States		https://ClinicalTrials.gov/show/NCT03873831
47	NCT01691066	Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorders	Behavioral: Infant Toddler Years PRT	Feasibility of a novel behavioral treatment|Acceptability of a novel behavioral treatment	Yale University|National Institute of Mental Health (NIMH)	All	12 Months to 15 Months   (Child)	Not Applicable	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1110009256|R03MH092617	September 2012	February 27, 2017	February 27, 2017	September 24, 2012		June 26, 2020	Yale Child Study Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT01691066
48	NCT03374072	Engaging Siblings of Adults With Autism in Future Planning		Completed	No Results Available	Autistic Disorder	Behavioral: Siblings FORWARD program|Behavioral: Information Only Condition	Change in Quality of Sibling Plan of Action|Sibling Future Planning Actions|Social Problem-Solving Skills Inventory-Revised|Family Communication about Future Planning|Future Planning Self-Efficacy|Sibling Barriers to Future Planning|Sibling Knowledge of Adult Services|Sibling Knowledge of Family Future Plan	Boston University Charles River Campus|National Institute of Mental Health (NIMH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	19	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	4366E|R34MH111489	February 1, 2017	January 31, 2021	January 31, 2021	December 15, 2017		May 28, 2021	Boston University, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03374072
49	NCT00090415	Early Characteristics of Autism		Completed	No Results Available	Autism|Autistic Disorder	Behavioral: Intensive behavioral therapy	Communication and social behavior scales; an early development interview; observations of parent/child interaction; and neuropsychological, cognitive, and adaptive behavioral measures	University of Washington|National Institute of Mental Health (NIMH)	All	18 Months to 30 Months   (Child)	Phase 1	48	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U54MH066399|DDTR BD-DD	April 2003	April 2008		August 27, 2004		June 19, 2012	University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00090415
50	NCT02184390	Parenting Your Young Child With Autism: A Web-Based Tutorial		Completed	No Results Available	Autistic Disorder	Other: On LIne Parent Training Tutorial	System Usability Scale|Autism Knowledge Test	Center for Psychological Consultation|National Institute of Mental Health (NIMH)	All	18 Months to 6 Years   (Child)	Not Applicable	104	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	5R44MH086936	May 2013	May 2015	September 2015	July 9, 2014		February 3, 2016	Center for Psychological Consulation, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02184390
51	NCT03847337	Can Novel Telemedicine Tools Reduce Disparities Related to Early Identification of Autism		Completed	Has Results	Autism Spectrum Disorder|Developmental Delay	Other: Telehealth-Screening Tool for Autism in Toddlers (STAT)|Other: Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)	Accurate Diagnosis of Autism Via Telemedicine|Accurate Diagnosis of Developmental Delay Via Telemedicine	Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)	All	15 Months to 3 Years   (Child)	Not Applicable	144	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic	190152|1R21MH118539-01	March 4, 2019	September 30, 2021	September 30, 2021	February 20, 2019	November 29, 2022	November 29, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03847337/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03847337/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03847337
52	NCT00004449	Randomized Study of Intensive One-on-one Behavioral Treatment for Preschool Aged Children With Autism		Completed	No Results Available	Autistic Disorder	Behavioral: intensive one-on-one behavioral treatment|Behavioral: Individualized in home parent training	Wechsler Preschool and Primary Scales of Intelligence, 3rd ed.|Bayley Scales of Infant Development|Merrill-Palmer Scale of Mental Tests|Reynell Developmental Language Scales|Vineland Adaptive Behavior Scales - Survey Edition	University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	2 Years to 3 Years   (Child)	Not Applicable	102	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R01MH048863|UCLA-HSPC-G930506611	May 1998	September 2004	April 2006	October 19, 1999		May 27, 2015			https://ClinicalTrials.gov/show/NCT00004449
53	NCT05047224	Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Tele-assessment + in-person assessment|Behavioral: Tele-assessment only	Diagnostic accuracy of the TAP|Validity of the TAP|Family perceptions of tele-assessment|Family satisfaction with diagnostic services|Family empowerment|Child service access and utilization	Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)	All	18 Months to 42 Months   (Child)	Not Applicable	720	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Diagnostic	210760|1R01MH127228-01	December 3, 2021	December 31, 2025	June 30, 2026	September 17, 2021		June 8, 2022	UC Davis MIND Institute, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT05047224
54	NCT00057408	A Controlled Study of Olanzapine in Children With Autism		Completed	No Results Available	Autistic Disorder	Drug: olanzapine (Zyprexa)|Drug: Placebo	Children's Psychiatric Rating Scale|Clinical Global Impressions|Aberant Behavior Checklist|Treatment Emergent Symptoms Scale|Olanzapine Untoward Effects Checklist|Abnormal Involuntary Movement Scale|Neurological Rating Scale	FDA Office of Orphan Products Development|National Institute of Mental Health (NIMH)	All	3 Years to 12 Years   (Child)	Phase 2	78	U.S. Fed|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2190	May 2003		September 2005	April 2, 2003		March 25, 2015	Drexel University College of Medicine c/o Friends Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00057408
55	NCT00873509	Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder	B-ACE	Completed	No Results Available	Autistic Disorder	Drug: Buspirone|Drug: Placebo	To evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children 2-6 years measuring the change from baseline in ADOS (Autism Diagnostic Observation Schedule) Composite Total scores compared to placebo at 6 months.|To evaluate the effects of twice-daily oral buspirone on the ADOS Composite calibrated severity score, social behavior, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there are age group differences in the effects of buspirone on social interaction, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there is a difference in the incidence of side effects and long term safety between the buspirone and placebo groups, and between the different dose groups.|To determine whether the whole brain PET measure of serotonin synthesis capacity is a predictor of buspirone effect.|To determine whether blood serotonin concentration is a predictor of buspirone effect.	Chugani, Diane C.|National Institute of Neurological Disorders and Stroke (NINDS)	All	2 Years to 6 Years   (Child)	Phase 2|Phase 3	166	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	10888|5U01NS061264	May 2009	January 2015	January 2015	April 1, 2009		July 26, 2016	University California Davis M.I.N.D. Institute, Sacramento, California, United States|Children's Hospital of Michigan Wayne State University, Detroit, Michigan, United States|New York University Langone Medical Center, New York, New York, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|University of Texas Southwestern, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT00873509
56	NCT00760812	Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders		Completed	No Results Available	Autistic Disorder	Behavioral: Early Social Interaction Project- PII|Behavioral: Early Social Interaction Project- IES	Child measures of autism symptoms, social communication, developmental level, and adaptive behavior|Parent report measures of family functioning, daily hassles, and treatment satisfaction	Florida State University|National Institute of Mental Health (NIMH)	All	16 Months to 20 Months   (Child)	Not Applicable	82	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	R01MH077730|1R01MH077730-01A2|1R01MH078165-01A2|DDTR B2-MBA	April 2007	May 2013	January 2014	September 26, 2008		July 27, 2022	Florida State University, Tallahassee, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT00760812
57	NCT05373173	Can a Novel Telemedicine Tool Reduce Disparities Related to the Identification of Preschool Children With Autism?	TAP-P	Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Tele-assessment + In-person assessment	Positive Predictive Value (PPV) of the TAP-Preschool|Negative Predictive Value (NPV) of the TAP-Preschool|Sensitivity of the TAP-Preschool|Specificity of the TAP-Preschool|Diagnostic Certainty: Tele-assessment|Family Satisfaction|Diagnostic Certainty: In-person assessment	Vanderbilt University Medical Center|National Institute of Mental Health (NIMH)	All	36 Months to 72 Months   (Child)	Not Applicable	150	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	220273|R21MH128790	June 1, 2022	December 15, 2024	December 15, 2024	May 13, 2022		October 21, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT05373173
58	NCT00086645	Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)		Completed	No Results Available	Autistic Disorder	Drug: citalopram hydrobromide|Other: placebo	Clinical Global Improvement|Safety Monitoring Uniform Research Form (SMURF)|Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS)|Repetitive Behavior Scale-Revised (RBS-R)|Parent Chief Complaint|Aberrant Behavior Checklist|Child and Adolescent Symptom Inventory: Anxiety and Depression scales|Behavioral Activation|Caregiver Strain Questionnaire|Vineland	Boston University|National Institute of Mental Health (NIMH)	All	5 Years to 17 Years   (Child)	Phase 2	149	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	U54MH066398	April 2004	October 2006	April 2007	July 13, 2004		March 10, 2017	UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore - Long Island Jewish Hospital, Great Neck, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00086645
59	NCT03419611	Word Learning in Children With Autism		Unknown status	No Results Available	Autistic Disorders Spectrum	Behavioral: Multi-Modal|Other: Treatment as Usual|Behavioral: High Intensity Multi-Modal	Expressive Word Acquisition|Change in Expressive Word Acquisition|Receptive Word Acquisition|Change in Receptive Word Acquisition|Communication Complexity Scale|Change in Communication Complexity Scale	University of Kansas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	5 Years to 10 Years   (Child)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	STUDY00140285|U54HD090216	November 1, 2016	May 31, 2021	May 31, 2021	February 5, 2018		April 29, 2019	University of Kansas, Lawrence, Kansas, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03419611/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT03419611
60	NCT00198107	Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism		Completed	Has Results	Autistic Disorder	Drug: Aripiprazole|Drug: Placebo|Drug: D-cycloserine	Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase|Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Score, Parent Report, Double-blind Phase|Mean Post-baseline Score on a Modified Version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Mean Vineland Maladaptive Behavior Subscales Total Score, Week 8|Mean Autism Diagnostic Observation Schedule (ADOS) Social Affect and Restricted and Repetitive Behaviors Total Score, Week 8|Mean Social Reciprocity Scale (SRS) Total Score, Week 8	Indiana University|National Institute of Mental Health (NIMH)	All	5 Years to 17 Years   (Child)	Phase 3	81	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R01MH072961|DSIR 82-SEDR	September 2005	September 2011	September 2011	September 20, 2005	March 29, 2019	April 9, 2019	Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00198107
61	NCT05396352	Cerebellum and Autism: Regional Specialization for Social and Executive Functions		Recruiting	No Results Available	Autism|Autism Spectrum Disorder	Device: Transcranial direct current stimulation	Reading the Mind in the Eyes Test Adult Version|Cyberball social ball-playing task|Flexible Item Selection Test|Functional MRI data	American University|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)	All	18 Years to 35 Years   (Adult)	Not Applicable	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	R15MH126404	January 1, 2022	December 31, 2024	December 31, 2024	May 31, 2022		June 1, 2022	American University, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT05396352
62	NCT02725619	CBT for Anxiety in Children With Autism		Recruiting	No Results Available	Autism Spectrum Disorder|Anxiety	Behavioral: CBT|Behavioral: PST	Pediatric Anxiety Rating Scale (PARS)|Clinical Global Impression - Improvement (CGI-I) scale|blood oxygenation level dependent signal (BOLD) during down-regulation versus passive viewing of affective images.|blood oxygenation level dependent signal (BOLD) during emotional face perception task	Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	8 Years to 14 Years   (Child)	Not Applicable	150	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	1211011144B|1R01HD083881-01A1	April 2016	December 2022	December 2022	April 1, 2016		December 3, 2021	Yale Child Study Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT02725619
63	NCT00376194	Mercury Chelation to Treat Autism		Withdrawn	No Results Available	Autism|Asperger's Disorder|Child Development Disorders, Pervasive	Drug: DMSA	Improvement in social reciprocity.|Improvement in language skills, decrease in blood mercury levels.	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	4 Years to 10 Years   (Child)	Phase 2	0	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	060238|06-M-0238	September 2006		March 2007	September 14, 2006		September 18, 2013	National Institute of Mental Health (NIMH), 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00376194
64	NCT03984513	Daily Living Skills Intervention for 9th and 10th Graders With Autism Spectrum Disorders		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Surviving and Thriving in the Real World|Behavioral: Program for the Education and Enrichment of Relational Skills	Vineland Adaptive Behavior Scales, 3rd Edition	Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	14 Years to 21 Years   (Child, Adult)	Not Applicable	48	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CIN-DUNCAN-2018-5606|1K23HD094855-01A1	September 25, 2018	February 28, 2022	February 28, 2022	June 13, 2019		August 10, 2022	Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT03984513
65	NCT01985022	Changing Developmental Trajectories Through Early Treatment		Recruiting	No Results Available	Autism Spectrum Disorders	Behavioral: PII with IES|Behavioral: IES	Child's social communication|Child's Autism Symptoms|Child's Developmental Level|Child's Adaptive Behavior|Parent Report	Emory University|National Institute of Mental Health (NIMH)	All	9 Months to 24 Months   (Child)	Not Applicable	108	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB00064779|P50MH100029-02	May 2013	July 2022	December 2022	November 15, 2013		June 10, 2021	Marcus Autism Center, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT01985022
66	NCT02361762	Gaming for Autism to Mold Executive Skills Project	GAMES	Completed	Has Results	Autism Spectrum Disorders	Behavioral: Computerized executive control training	Change Task - Stop Signal Reaction Time|Stroop Task (Difference in Percentage of Correct Responses for Congruent Minus Incongruent Trials)|Event-related Potentials Assessed During Child Attention Network Flanker Task|BRIEF Parent Survey (Global Executive Composite)|Backward Digit Span (Scaled Score)|Social Attribution Task (SAT) - Problem Solving Scale|Theory of Mind Composite: Perception Knowledge, Location Change False Belief, Unexpected-contents False Belief|TOM Test (Theory of Mind Test)|Social Skills Improvement System-Parent (SSIS) - Social Standard Score|Narrative Language Task|Performance on Hungry Donkey Task Assessed as Ratio of Safe to Risky Selections|Event-related Potentials Assessed During Cued Go/Nogo Task	Boston Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	7 Years to 11 Years   (Child)	Not Applicable	70	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	P00014188|R00HD071966	February 2015	November 2017	November 2017	February 12, 2015	February 20, 2019	July 28, 2021	Boston Children's Hospital: Labs of Cognitive Neuroscience- Faja Lab, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02361762/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02361762
67	NCT04218331	Boosting Language Outcomes of Minimally Verbal Children With ASD (BLOOM)	BLOOM	Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: JASPER|Behavioral: PROMPT	Change in spontaneous socially communicative utterances (SCU) using the Elicitation of Language Samples for Analysis (ELSA).|Change in number of novel and distinct word root (NDWR), and presence of word combinations at age six based on the ELSA language sample.|Change in number of novel and distinct word root (NDWR) based on the Preschool Language Scales-5 (PLS-5).|Presence of word combinations at age six based on the Preschool Language Scales-5 (PLS-5)	University of California, Los Angeles|National Institutes of Health (NIH)	All	48 Months to 66 Months   (Child)	Not Applicable	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-000806	April 29, 2021	June 30, 2024	June 30, 2024	January 6, 2020		October 12, 2022	UCLA Semel Institute, Los Angeles, California, United States|UCLA, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04218331
68	NCT02276534	SENSE Theatre Intervention for Children With Autism Spectrum Disorder (ASD)		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: SENSE Theatre|Behavioral: Delayed Intervention	NEPSY Memory for faces|Measurement of Salivary Cortisol levels|Event Related Potentials (ERP) incidental memory task|Social Responsiveness Scale|Peer Interaction Playground Paradigm|Adaptive Behavior Assessment System|Parenting Stress Index|Clinical Evaluation of Fundamentals Recalling Sentences subtest|Peabody Picture Vocabulary Test	Vanderbilt University|National Institute of Mental Health (NIMH)|Vanderbilt University Medical Center	All	8 Years to 16 Years   (Child)	Not Applicable	136	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	110082	August 2014	May 2017	May 2017	October 28, 2014		June 14, 2017	Vanderbilt Kennedy Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT02276534
69	NCT04869540	Improving Transition Outcomes for Youth With ASD in a Medicaid Accountable Care Organization		Withdrawn	No Results Available	Autism Spectrum Disorder	Other: Usual care|Other: 'Got Transition' toolkit and resources|Behavioral: PSE intervention	Baseline Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) ASD|6 months PEDI-CAT ASD|Social skills|Cognition|Parent Functioning and Depressive Symptoms assessed by SAS-SR|Parent Functioning and Depressive Symptoms assessed by QIDS|Family Empowerment|Perceived parental stress|Parental stress|Perceived youth stress|Parental coping strategies|Youth coping strategies|Vocational and Educational Activities|Health Care Transition Readiness and Family Perception of Health Care Integration using TRAQ|Health Care Transition Readiness and Family Perception of Health Care Integration using the Pediatric Integrated Care Survey (PICS)	Boston Medical Center|National Institute of Mental Health (NIMH)	All	14 Years and older   (Child, Adult, Older Adult)	Not Applicable	0	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	H-41693|5K18MH120457	April 2022	December 2022	December 2022	May 3, 2021		April 22, 2022			https://ClinicalTrials.gov/show/NCT04869540
70	NCT05154981	Partners in School: Promoting Continuity Across Home and School		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Education communication skills (ECS) training|Behavioral: Partners in School	Adapted LEAPS Questionnaire about ECS training (A-LEAPS)|Parent-Teacher Relationship Scale-Second Edition (PTRS-II)|Parent-Teacher Alliance Questionnaire (PTAQ)|Participation in Problem Solving Scale (PPSS)|Change from Baseline Fidelity (to Student Intervention Plan) at 3 weeks|Change from Baseline Alignment (of Student Intervention Plan) at 3 weeks|Frequency and Severity Form (FSF)|Pervasive Developmental Disorder Behavior Inventory (PDDBI)|Goal Attainment Scaling (GAS)|Family-Professional Partnership Scale (FPPS)|Self-Efficacy with Communication Form (SECF)|Consultant Adherence	New York State Psychiatric Institute|National Institute of Mental Health (NIMH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	72	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	8302|5K23MH119331-04	September 15, 2022	June 15, 2023	August 15, 2023	December 13, 2021		November 14, 2022	Research Foundation for Mental Hygiene at the New York State Psychiatric Institute, New York, New York, United States		https://ClinicalTrials.gov/show/NCT05154981
71	NCT01784263	Schema, Emotion, and Behavior Therapy for Children	SEBASTIEN	Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Individual Cognitive Behavioral Therapy|Behavioral: Standard Community Treatment	Playground Observation of Peer Engagement scale	University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	9 Years to 13 Years   (Child)	Not Applicable	70	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	11-002061|1R01MH094391-01A1	March 1, 2012	February 1, 2017	September 1, 2017	February 5, 2013		September 7, 2018	Jeffrey Wood, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT01784263
72	NCT04312932	Fatty Acid Supplementation in Children With ASD (Study 2)	Omega Heroes	Enrolling by invitation	No Results Available	Autism Spectrum Disorder	Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo	Pervasive Developmental Disorder Behavior Inventory (PDDBI) - Autism Composite|Vineland Adaptive Behavior Scales 2nd ed. (modified timeframe of 90 days)|Pervasive Developmental Disorder (PDD) Behavior Inventory (PDDBI) - Aggressiveness Problems|Preschool Language Scales - 5 (PLS-5)|Childhood Autism Rating Scale (CARS2) (2nd ed.)|Autism Impact Measure	Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital	All	2 Years to 6 Years   (Child)	Phase 2	96	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB17-00517-2	December 1, 2021	October 31, 2023	January 31, 2024	March 18, 2020		December 20, 2022	Nationwide Children's Hospital, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04312932
73	NCT01908686	Pivotal Response Treatment for Children With Autism Spectrum Disorders	PRT	Completed	No Results Available	Autism Spectrum Disorders	Behavioral: Pivotal Response Training	Social Responsiveness Scale (SRS) Total Score|Clinical Global Impressions Scale (CGI-I)|Autism Diagnostic Observation Schedule (ADOS) Comparison Score|Aberrant Behavior Checklist (ABC)|Vineland Domain Scores|Change in Eye Tracking (ET) patterns|Change in neural response to social stimuli using fMRI	Yale University|National Institute of Neurological Disorders and Stroke (NINDS)	All	4 Years to 35 Years   (Child, Adult)	Not Applicable	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	1106008625|2R01NS035193-18	May 2012	December 1, 2019	March 1, 2020	July 26, 2013		August 14, 2020	Yale Child Study Center - Autism Program, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT01908686
74	NCT00178503	Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children		Completed	Has Results	Autism|Attention Deficit Disorder With Hyperactivity	Drug: Methylphenidate-extended release|Drug: Methylphenidate-immediate release|Other: Placebo	Mean Conners' Teacher ADHD Index T Score by Dose|Mean Continuous Performance Test (CPT)-Commission Errors by Dose|Mean Conners' Parent ADHD Index T Score by Week	The University of Texas Health Science Center, Houston|National Institute of Mental Health (NIMH)	All	7 Years to 12 Years   (Child)	Phase 2|Phase 3	24	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R01MH072263|DDTR B2-NDA	September 2005	May 2011	May 2011	September 15, 2005	May 7, 2013	May 9, 2013	University of Texas Health Science Center at Houston, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00178503
75	NCT03550209	Fatty Acid Supplementation in Children With ASD	Omega Heroes	Completed	Has Results	Autism Spectrum Disorder	Drug: LCPUFA Oil Supplement|Dietary Supplement: Canola Oil Placebo	Bioavailability|Safety (Adverse Events)|Biological Signatures	Sarah Keim|National Center for Complementary and Integrative Health (NCCIH)|Nationwide Children's Hospital	All	2 Years to 6 Years   (Child)	Phase 2	72	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB17-00517|R61AT009632	June 28, 2018	January 10, 2020	January 10, 2020	June 8, 2018	April 2, 2021	August 3, 2021	Nationwide Children's Hospital, Columbus, Ohio, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/Prot_SAP_002.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03550209
76	NCT00183339	Early Intervention With Fluoxetine in Autism		Completed	Has Results	Autistic Disorder	Drug: Fluoxetine|Drug: Placebo	Rate of Recruitment|Rate of Attrition|Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire|Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I)	University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)	All	30 Months to 58 Months   (Child)	Phase 2	18	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	U54MH066418	July 2005	February 2008	February 2008	September 16, 2005	March 26, 2014	March 26, 2014	Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00183339
77	NCT03274622	Efficacy of IMPACT in Infant Siblings of Children With ASD	IMPACT	Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Impact Parent Training|Behavioral: No Impact	Growth in communication|Growth in play|Motor imitation|Autism social affect symptomatology|Language delay|language level|parent implementation of ImPACT treatment	Vanderbilt University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	12 Months to 18 Months   (Child)	Not Applicable	97	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	140924|1R01DC013767-01	February 16, 2016	August 30, 2019	August 30, 2019	September 7, 2017		October 2, 2019	Vanderbilt University, Nashville, Tennessee, United States|University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03274622
78	NCT01190917	Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)		Completed	No Results Available	Autism|Autism Spectrum Disorder	Behavioral: Cognitive Behavioral Therapy (CBT)|Behavioral: Play Therapy	Diagnostic Analysis of Nonverbal Accuracy-2* (DANVA2)|Reading the Mind in the Eyes Task - Child Version|Functional Magnetic Resonance Imaging (fMRI)|Social Responsiveness Scale (SRS)|Strange Stories Task|Vineland Adaptive Behavior Scales, Second Edition (Vineland II)|Autism Diagnostic Observation Schedule (ADOS)|Direct Observation|Peer generalization assessment	Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)	All	8 Years to 11 Years   (Child)	Not Applicable	50	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	GCO #09-0859|R21MH089236	September 2009	September 2012	September 2012	August 30, 2010		October 2, 2012	Mount Sinai School of Medicine - Seaver Autism Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01190917
79	NCT05187377	A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism		Recruiting	No Results Available	Phelan-McDermid Syndrome|Autism Spectrum Disorder (ASD)	Drug: Growth Hormone|Drug: Saline	Visual Evoked Potentials (VEP)|Aberrant Behavior Checklist (ABC) Social Withdrawal Subscale|Repetitive Behavior Scale-Revised (RBS-R)|Sensory Profile|Sensory Assessment for Neurodevelopmental Disorders (SAND)	Icahn School of Medicine at Mount Sinai|National Institute of Neurological Disorders and Stroke (NINDS)	All	2 Years to 12 Years   (Child)	Phase 2	45	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY-18-00245|R01NS105845|GCO 17-1159	January 19, 2022	July 1, 2024	July 1, 2024	January 11, 2022		July 26, 2022	Seaver Autism Center for Research & Treatment, New York, New York, United States		https://ClinicalTrials.gov/show/NCT05187377
80	NCT00927030	Melatonin for Sleep in Children With Autism	NICHD	Completed	No Results Available	Autistic Disorder|Insomnia	Drug: supplemental liquid melatonin|Drug: flavored liquid or liquid supplemental melatonin	Determine dose-response, tolerability, and adverse effects of melatonin in 30 children with autism.|A sub-set of 12 children will be studied to characterize the pharmacokinetic profile of orally administered melatonin.|A group of behavioral and parental stress measures will be piloted for the participants in this study.	Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	4 Years to 10 Years   (Child)	Phase 1	17	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	071269	January 2008	April 2010	October 2010	June 24, 2009		July 2, 2012	Vanderbilt Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT00927030
81	NCT00047697	Donepezil HCl & Cognitive Deficits in Autism		Completed	Has Results	Autistic Disorder	Drug: Donepezil HCl|Drug: Placebo	Cognitive Assessment: TMT|Cognitive Assessment: EOWVT Standard Score|Cognitive Assessment: CVLT	University of Pittsburgh|National Institute of Mental Health (NIMH)	All	8 Years to 17 Years   (Child)	Phase 2	34	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R21MH064941|DSIR CT-M3	October 2002	August 2006	August 2006	October 16, 2002	October 5, 2017	October 5, 2017	Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00047697
82	NCT02301195	Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder		Completed	No Results Available	Autism Spectrum Disorder|Child Development Disorders, Pervasive	Other: Therapeutic horseback riding|Other: Barn Activity Intervention	Change in Aberrant Behavior Checklist-Community (Irritability subscale)|Change in Aberrant Behavior Checklist-Community (Hyperactivity, Lethargy, Stereotypy subscale)|Change in Social Responsiveness|Change in Systematic Analysis of Language Transcript|Change in Peabody Picture Vocabulary Test-4|Change in Bruininks-Oseretsky Test of Motor Proficiency-2nd Ed. (Short form)|Change In Sensory Integration and Praxis Test (Praxis on verbal command & Postural Praxis subtests)|Change in Vineland Adaptive Behavior Scales Interview 2nd Ed.	University of Colorado, Denver|National Institute of Nursing Research (NINR)	All	6 Years to 16 Years   (Child)	Not Applicable	209	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	07-1148|1R01NR012736	October 2010	June 19, 2014	June 19, 2014	November 25, 2014		October 8, 2021			https://ClinicalTrials.gov/show/NCT02301195
83	NCT04881656	Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes		Recruiting	No Results Available	Autism Spectrum Disorder	Other: Help is in Your Hands	Parent Stress Index 4th Edition, Short Form|Parent Sense of Competence|Telehealth Usability Questionnaire	University of California, Davis|National Center for Advancing Translational Sciences (NCATS)|National Institute of Mental Health (NIMH)	All	6 Months to 99 Years   (Child, Adult, Older Adult)	Not Applicable	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	1749700	September 1, 2021	May 31, 2023	May 31, 2033	May 11, 2021		February 2, 2022	University of California Davis Health, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT04881656
84	NCT00926471	Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders		Completed	No Results Available	Autistic Disorder|Child Development Disorders, Pervasive	Behavioral: Cognitive Behavioral Therapy (CBT) Program	Child and Adolescent Symptom Inventory 20-Item Anxiety Subscale (CASI-20)	Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH)	All	12 Years to 17 Years   (Child)	Phase 1	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	K01MH079945|DDTR B2-MBA	September 2008	May 2011	January 2013	June 23, 2009		November 7, 2013	Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States		https://ClinicalTrials.gov/show/NCT00926471
85	NCT00965068	Cholesterol in ASD: Characterization and Treatment		Completed	No Results Available	Autism|Asperger Disorder|PDD-NOS	Other: Cholesterol	Behavioral Changes	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)	All	4 Years to 12 Years   (Child)	Phase 1|Phase 2	44	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment	090203|09-CH-0203	July 28, 2009		November 14, 2013	August 25, 2009		July 5, 2018	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00965068
86	NCT04764539	Video Assisted Speech Technology to Enhance Motor Planning for Speech	VAST	Completed	No Results Available	Autism Spectrum Disorder|Apraxia of Speech	Behavioral: Video Assisted Speech Therapy (VAST)	Increased mean length of utterance (MLU)|percentage of correctly transcribed words using automatic speech recognition|change speech intelligibility|Generalization of skills	iTherapy, LLC|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	4 Years to 8 Years   (Child)	Phase 1	6	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1R43DC018447-01	December 1, 2019	November 30, 2020	November 30, 2020	February 21, 2021		February 21, 2021	All research was conducted via tele-research due to COVID-19, Vallejo, California, United States		https://ClinicalTrials.gov/show/NCT04764539
87	NCT04068688	Tailoring Treatment Targets for Early Autism Intervention in Africa		Completed	Has Results	Autism Spectrum Disorder	Behavioral: Early Start Denver Model (ESDM)|Behavioral: Telehealth coaching	Supported Joint Engagement Measured by the Joint Engagement Rating Inventory (JERI)|Coordinated Joint Engagement Measured by the Joint Engagement Rating Inventory (JERI)|Symbol-infused Joint Engagement Measured by the Joint Engagement Rating Inventory (JERI)|Fluency and Connectedness Measured by the Joint Engagement Rating Inventory (JERI)|Shared Routines and Rituals Measured by the Joint Engagement Rating Inventory (JERI)|Scaffolding Measured by the Joint Engagement Rating Inventory (JERI)|Following in on a Child's Focus Measured by the Joint Engagement Rating Inventory (JERI)|Caregiver Affect Measured by the Joint Engagement Rating Inventory (JERI)|Initiation of Joint Attention (IJA) Measured by the Early Social Communication Scales (ESCS)|Response to Joint Attention (RJA) Measured by the Early Social Communication Scales (ESCS)|Language and Communication Developmental Quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Personal-Social-Emotional Developmental Quotient on the Griffiths Scales of Child Development 3rd Edition (Griffiths-III)|Socialization Subscale Standard Score on the Vineland Adaptive Behavior Scales - 3rd Edition (VABS-3)|Communication Subscale Standard Score on the Vineland Adaptive Behavior Scales - 3rd Edition (VABS-3)|Acceptability of Telehealth Intervention (as Measured by the Acceptability of Intervention Measure, AIM)|Appropriateness of Telehealth Intervention (as Measured by the Intervention Appropriateness Measure, IAM)|Feasibility of Intervention (as Measured by the Feasibility of Intervention Measure, FIM)|Fidelity of Intervention Delivery, as Measured by the Caregiver ESDM Fidelity Rating System	Duke University|University of Cape Town|National Institute of Mental Health (NIMH)	All	18 Months to 72 Months   (Child)	Not Applicable	73	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	Pro00103045|1R21MH120696	September 1, 2019	August 26, 2021	August 26, 2021	August 28, 2019	December 2, 2022	December 2, 2022	University of Cape Town, Cape Town, West Cape, South Africa	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04068688/Prot_SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04068688/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04068688
88	NCT01154777	Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism		Unknown status	No Results Available	Autism	Behavioral: Neurofeedback training	Level of normalization of brainwaves based upon QEEG	Institute for Personal Excellence, P.A.|Life Quality Resources|National Institute of Mental Health (NIMH)	All	6 Years to 18 Years   (Child, Adult)	Phase 1	30	Other|NIH	Interventional	Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NFB6-18Autism	July 2011	June 2016	December 2016	July 1, 2010		October 5, 2010	Institute for Personal Excellence, P.A., Raleigh, North Carolina, United States|Life Quality Resources, Raleigh, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01154777
89	NCT00584701	Pharmacogenomics in Autism Treatment	PG	Completed	Has Results	Autism	Drug: Risperidone	Percent Change of ABC - Irritability Subscale Score|Exon Expression Positively or Negatively Correlated With Percentage Improvement in ABC-I	University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)	All	4 Years to 18 Years   (Child, Adult)	Phase 2|Phase 3	49	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200715817-1|R21MH080026	January 2008	May 2009	May 2009	January 2, 2008	July 24, 2012	July 24, 2012	UC San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT00584701
90	NCT01768806	Randomized Controlled Trial of the P.L.A.Y. (Play and Language for Autistic Youngsters) Project Intervention for Autism	PLAY	Completed	No Results Available	Autism|Autism Spectrum Disorder	Behavioral: PLAY Project Intervention for Autism|Behavioral: Special education pre-school	Reduction in autism severity as measured by the Autism Diagnostic Observation Scale (ADOS)|Language as measured by the MacArthur-Bates Communicative Developmental Inventories|Vineland Adaptive Behavior Scale	Richard Solomon MD, Plc|Michigan State University|National Institute of Mental Health (NIMH)	All	3 Years to 5 Years   (Child)	Not Applicable	112	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	3125511|2R44MH078431-02A1	September 2009	June 2012	December 2012	January 15, 2013		January 17, 2013	Ann Arbor Center for Developmental and Behavioral Pediatrics, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT01768806
91	NCT02695693	RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: TeachTown|Behavioral: Discrete Trial Training|Behavioral: Pivotal Response Training|Behavioral: Teaching in Functional Routines	Differential Abilities Scale, 2nd Edition|Bracken School Readiness Assessment, 3rd Edition	University of Pennsylvania|National Institute of Mental Health (NIMH)|The School District of Philadelphia	All	5 Years to 9 Years   (Child)	Not Applicable	212	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R01MH106175	April 2015	June 2017	June 15, 2018	March 1, 2016		April 18, 2019			https://ClinicalTrials.gov/show/NCT02695693
92	NCT01945957	Brain Imaging of Intranasal Oxytocin Treatment in Autism		Completed	No Results Available	Autism Spectrum Disorders	Drug: Oxytocin	Aim 1a. fMRI Activation Analysis/Connectivity|Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking)|Plasma Oxytocin (OT) levels in aim 1b. and 2b.|Salivary Oxytocin (OT) levels for all aims.|SRS-Social Responsiveness Scale|Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV)|ABC-lethargy/social withdrawal subscale	University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	6 Years to 18 Years   (Child, Adult)	Phase 1	33	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other	12-2622|U54HD079124-01	September 2014	January 2017	January 2017	September 19, 2013		April 25, 2017	The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01945957
93	NCT05608083	HEARTS R34 Feasibility Study, Autistic Participants	HEARTS-R34	Not yet recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: HEARTS classes|Behavioral: Online discussion group	Change in engaging in perspective-taking related to rejection at 6 weeks|Change in engaging in perspective-taking related to rejection at 12 weeks|Change in resilience capacity given social rejection at 6 weeks|Change in resilience capacity given social rejection at 12 weeks|Change in satisfaction with close relationships at 6 weeks|Change in satisfaction with close relationships at 12 weeks|Change in motivation to interact socially at 6 weeks|Change in motivation to interact socially at 12 weeks|Participant satisfaction with study participation|Participant feelings of acceptability of study intervention|Participant rating of content acceptability|Teacher rating of participant engagement and satisfaction|Teacher rating of intervention acceptability	Boston University|National Institute of Mental Health (NIMH)|University of Alabama at Birmingham	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	H-12345	December 2022	December 2025	December 2025	November 8, 2022		November 8, 2022			https://ClinicalTrials.gov/show/NCT05608083
94	NCT03307057	Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Social Communication Growth Charts (SCGC)|Behavioral: Parent-Implemented (P-I) Condition|Behavioral: Clinician-Implemented (C-I) Condition	Change in Measure of Active Engagement and Transactional Supports (MAETS) Score|Change in Communication and Symbolic Behavior Scales (CSBS) Score|Change in Autism Diagnostic Observation Schedule Score|Change in Mullen Scales of Early Learning Score|Change in Vineland-3 Adaptive Behavior Scales Score|Change in Measure of Active Engagement and Transactional Supports (MAETS) in Parents of Children Showing Signs of ASD|Change in Communication and Symbolic Behavior Scales (CSBS) Score in Children Showing Signs of ASD|Change in Autism Diagnostic Observation Schedule Score in Children Showing Signs of ASD|Change in Mullen Scales of Early Learning Score in Children Showing Signs of ASD|Change in Vineland-3 Adaptive Behavior Scales Score in Children Showing Signs of ASD	Emory University|National Institute of Mental Health (NIMH)	All	6 Months to 6 Months   (Child)	Not Applicable	300	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB00098127|P50MH100029	February 1, 2018	April 2023	April 2023	October 11, 2017		September 26, 2022	Marcus Autism Center, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03307057
95	NCT02416323	Effectiveness and Implementation of a Mental Health Intervention for ASD	AIM HI	Completed	No Results Available	Autism Spectrum Disorder	Other: AIM HI Training	Change since baseline in child behaviors on the Eyberg Child Behavior Inventory (ECBI)|Change since baseline in child behaviors on the Social Skills Improvement System (SSIS) Competing Behavior Scale	University of California, San Diego|National Institute of Mental Health (NIMH)	All	5 Years to 13 Years   (Child)	Not Applicable	609	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	2011-4131|R01MH094317	April 2012	February 2018	February 2018	April 15, 2015		July 9, 2018	Child and Adolescent Services Research Center, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT02416323
96	NCT03589898	Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin		Completed	No Results Available	Autism Spectrum Disorder	Drug: Gabapentin	Cortical GABA in Anterior Cingulate Cortex|Cortical GABA in Right Anterior Insula|Cortical Glx in Anterior Cingulate Cortex|Cortical Glx in Right Anterior Insula	University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)|Johns Hopkins University	All	13 Years to 17 Years   (Child)	Early Phase 1	19	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	H00012656|1K23MH113008-01A1	September 14, 2017	August 31, 2022	August 31, 2022	July 18, 2018		November 2, 2022	University of Massachusetts Medical School, Worcester, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03589898
97	NCT01028820	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders	AripfMRI	Completed	Has Results	Autism Spectrum Disorder	Drug: Aripiprazole	Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version|Total Repetitive Behavior Scale - Revised (RBS_R)	University of North Carolina, Chapel Hill|Duke University|National Institute of Mental Health (NIMH)	All	10 Years to 55 Years   (Child, Adult)	Phase 4	13	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	090795|K23MH081285	August 2009	January 2011	January 2011	December 9, 2009	March 11, 2014	March 11, 2014	University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01028820
98	NCT02046889	A Bicycle Training Intervention		Completed	No Results Available	Autism Spectrum Disorder|Down Syndrome	Behavioral: Bicycle Training Intervention	Independent bicycle riding ability|Bicycle riding effects on physical activity|Bicycle riding effects on leg strength|Bicycle riding effects on static balance ability|Participation following learning to ride a two-wheeled bicycle|Bicycle riding effects on sleep behavior	University of Michigan|National Institutes of Health (NIH)	All	9 Years to 18 Years   (Child, Adult)	Not Applicable	155	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CMBDS2012|H133G090006	June 2010	August 2012	December 2012	January 28, 2014		January 28, 2014	Southbend, Indiana, United States|Ann Arbor, Michigan, United States|Grand Rapids, Michigan, United States		https://ClinicalTrials.gov/show/NCT02046889
99	NCT03514784	Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder		Recruiting	No Results Available	Autism Spectrum Disorder|Gastrointestinal Symptoms	Drug: BB-12 with LGG (Higher Dose)|Drug: Placebo|Drug: BB-12 with LGG (Lower Dose)	Effects of BB-12+LGG at different doses on adverse events (safety)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors with Aberrant Behavior Checklist (ABC)|Effects of BB-12+LGG at different doses on irritability and maladaptive behaviors measured with the Social Responsiveness Scale-2	The University of Texas Health Science Center, Houston|Texas Higher Education Coordinating Board|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	4 Years to 16 Years   (Child)	Phase 1|Phase 2	70	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	HSC-MS-17-0995|R01HD095158-02	May 2016	September 2025	September 2025	May 2, 2018		June 10, 2022	UTHealth, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03514784
100	NCT01751698	Adaptive Interventions for Minimally Verbal Children With ASD in the Community	AIM-ASD	Completed	No Results Available	Autism	Behavioral: JASP-EMT|Behavioral: DTT	Primary Outcome 1: Language Sample|Secondary Aim 1: Joint Engagement|Secondary Outcome 2: Number of Unique Words (Vocabulary)|Secondary Outcome 3: Object Play	University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	54 Months to 96 Months   (Child)	Not Applicable	192	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	R01HD073975	January 2013	June 2017	December 2017	December 18, 2012		October 11, 2018	University of California, Los Angeles, Los Angeles, California, United States|University of Rochester, Rochester, New York, United States|Weill Cornell Medical College, White Plains, New York, United States|Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT01751698
101	NCT04258254	The Effect of Play on Social and Motor Skills of Children With ASD		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Multimodal|Behavioral: General|Behavioral: Standard of Care	Change in cortical activation during the Rhythmic Synchrony task|Change in cortical activation during a building task|Change in joint attention scores|Change in gross-motor performance scores|Change in praxis errors|Change in movement quality and prosocial behaviors|Change in distance covered during walking|Changes in time taken to complete the task|Developmental Coordination Disorder-Questionnaire|Sensory Processing Measure (SPM)	University of Delaware|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)	All	5 Years to 15 Years   (Child)	Not Applicable	45	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	1539736-1|3P20GM103446-19S1	June 4, 2020	February 28, 2022	February 28, 2022	February 6, 2020		January 6, 2021	University of Delaware, Newark, Delaware, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04258254/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04258254
102	NCT05344378	Refining and Implementing Technology-Enhanced Family Navigation to Promote Early Access and Engagement With Mental Health Services for Youth With Autism	ATTAIN NAV	Enrolling by invitation	No Results Available	Autism Spectrum Disorder|Implementation Science|Mental Health|Behavioral Health	Behavioral: ATTAIN NAV Technology-Enhanced Family Navigation Model	Acceptability of Intervention Measure (AIM)|Feasibility of Intervention Measure (FIM)|Appropriateness of Intervention Measure (AIM)|the Navigation Satisfaction Tool (NAVSAT)|Navigator Fidelity|Eyberg Child Behavior Inventory (ECBI)|Parent Activation Measure for Developmental Disabilities (PAM-DD)|Parent Participation Engagement Measure	University of California, San Diego|Kaiser Permanente|National Institute of Mental Health (NIMH)	All	4 Years to 16 Years   (Child)	Not Applicable	190	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	200147|1R34MH120190-01A1	May 1, 2022	April 30, 2023	June 30, 2023	April 25, 2022		November 1, 2022	UCSD, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT05344378
103	NCT02275715	Treatment of Feeding Problems in Children With Autism	PT-F	Completed	No Results Available	Treatment of Feeding Problems in Children With ASD	Behavioral: Parent Training Program	Number of Subjects with Complete Data|Treatment Fidelity|Parent Adherence|Brief Autism Mealtime Behavior Inventory (BAMBI)	University of Florida|University of Rochester|National Institute of Mental Health (NIMH)	All	2 Years to 7 Years   (Child)	Not Applicable	54	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB201400831-N	February 2015	January 25, 2017	June 25, 2017	October 27, 2014		April 5, 2018	University of Florida, Gainesville, Florida, United States|University of Rochester, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT02275715
104	NCT02409303	An SRT Model for Early Access to ASD Intervention		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Screen-Refer-Treat Intervention	Change in rates of ASD screening by PCPs at the 18-month Well-Child visit from baseline (pre-SRT intervention) to post-SRT intervention|Change in rates of referral for early intervention services by PCPs at the 18-month Well-Child visit from baseline (pre-SRT intervention) to post-SRT intervention|Change in percent of toddlers at risk for ASD recieving ASD-specialized behavioral intervention before 24 months from baseline (pre-SRT intervention) to post-SRT intervention|Change in average age at which children receive an ASD diagnosis from baseline (pre-SRT intervention) to post-SRT intervention|Change in levels of parenting stress, parenting efficacy, health quality of life, and satisfaction with the healthcare system from baseline (pre-SRT intervention) to post-SRT intervention|Change in levels of pivotal social-communicative behaviors in toddlers at risk for ASD from baseline (pre-SRT intervention) to post-SRT intervention	University of Washington|Seattle Children's Hospital|National Institute of Mental Health (NIMH)	All	16 Months and older   (Child, Adult, Older Adult)	Not Applicable	627	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	47892|R01MH104302-01	July 2015	June 2019	June 2019	April 6, 2015		November 3, 2022	University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02409303
105	NCT00251303	Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders		Completed	Has Results	Obsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental Disorder	Drug: Riluzole|Drug: Placebo	Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)|Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS)	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	7 Years to 17 Years   (Child)	Phase 2	78	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	050225|05-M-0225	August 2005	February 2012	February 2012	November 9, 2005	July 15, 2014	July 15, 2014	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00251303
106	NCT03605368	VR Intervention to Improve Police Safety		Recruiting	No Results Available	Autism Spectrum Disorder|Autism	Behavioral: Virtual Reality Intervention|Behavioral: Video Modeling Intervention	Change in Live Police Interaction Assessment Scores from Pre-to-Post treatment|Change in Police Interaction Knowledge|Learned skill improvements - Phase IIb only	Children's Hospital of Philadelphia|Floreo, Inc.|National Institute of Mental Health (NIMH)	All	12 Years to 60 Years   (Child, Adult)	Not Applicable	96	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	17-014387|1R42MH115539-01	November 28, 2017	August 2022	August 2022	July 30, 2018		November 26, 2021	Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03605368
107	NCT03242772	Impact of Combined Medication and Behavioral Treatment for ASD & ADHD		Terminated	Has Results	Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder	Drug: Amphetamine|Behavioral: ESDM informed parent coaching|Drug: Placebo Oral Tablet	Change in Amount and Quality of Joint Engagement Between the Child and Parent During a Semi-structured 6 Minute Parent Child Interaction Task|Change in Mean Composite Score (Socialization and Communication Subscales Standard Scores) of the Vineland Adaptive Behavior Scale - 3rd Edition, Interview Version (VABS-3)|Change in ADHD Symptoms Using Preschool or School Age ADHD Rating Scale (ADHD-RS) Total Score|Changes in Objective Measures of Social Attention and Social Engagement Using Eye Gaze Tracking	Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	36 Months to 131 Months   (Child)	Phase 2	18	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Pro00085179|1P50HD093074-01	December 14, 2018	December 28, 2020	April 19, 2021	August 8, 2017	March 9, 2022	March 22, 2022	Duke Center for Autism and Brain Development, Durham, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03242772/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03242772/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03242772
108	NCT03525951	Parent-Level Predictors of Early Language Interaction Quality and Intervention Outcomes		Recruiting	No Results Available	Language Development Disorders|Autism Spectrum Disorder	Behavioral: Enhanced Milieu Teaching|Other: no intervention comparison group	Parental Language Stimulation Strategies (Study 2; Hybrid)|Parental Language Stimulation Strategies (Study 1; Remote)|Adult-Child Conversational Turns (Study 2; Hybrid)|Adult-Child Conversational Turns (Study 1; Remote)	Temple University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	30 Months and older   (Child, Adult, Older Adult)	Not Applicable	350	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	24997|1K23DC017763-01A1	March 22, 2021	November 30, 2024	November 30, 2024	May 16, 2018		May 6, 2022	Temple University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03525951
109	NCT00198120	Safety and Effectiveness of D-Cycloserine in Children With Autism		Completed	No Results Available	Autistic Disorder	Drug: D-cycloserine|Drug: Placebo	Change in Clinical Global Impressions (CGI) Global Improvement|Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC)	Indiana University|National Institute of Mental Health (NIMH)|National Alliance for Research on Schizophrenia and Depression|Indiana University School of Medicine	All	3 Years to 12 Years   (Child)	Phase 3	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	K23MH068627|0305-30|DDTR BK-TKND	February 2004	September 2007	August 2010	September 20, 2005		April 12, 2016	Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00198120
110	NCT03842332	Building Resilience and Appropriate Independence in Young Adults With Autism		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Life Skills and Resilience Program	Change in Baseline Resilience at 3-6 months|Change in Baseline General Family Functioning at 3-6 months|Change in Baseline Self Efficacy at 3-6 months|Change in Baseline Pediatric Quality of Life at 3-6 months|Change in Baseline Satisfaction with Social Roles at 3-6 months and Activities (v2.0)|Change in Baseline Employment Status	University of California, San Francisco|National Institutes of Health (NIH)|Golden Gate Regional Center|The Arc San Francisco|National Institute of Mental Health (NIMH)	All	18 Years to 26 Years   (Adult)	Not Applicable	42	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P0527544|R21MH115375	January 25, 2019	May 31, 2021	May 31, 2021	February 15, 2019		April 28, 2021	The Arc, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03842332
111	NCT01250938	Effectiveness of Early Intervention in an Underserved Population	ESI-CO	Unknown status	No Results Available	Autism Spectrum Disorders	Behavioral: ESI - Community Outreach	Caregiver Transactional Support|Child Outcome|Caregiver Outcome	Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)|Autism Speaks|Florida State University	All	24 Months to 54 Months   (Child)	Not Applicable	44	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1108011843|Autism Speaks 5766|R01MH078165	July 2009	May 2019	May 2019	December 1, 2010		July 23, 2018	Florida State University, Tallahassee, Florida, United States|Weill Cornell Medical College, White Plains, New York, United States		https://ClinicalTrials.gov/show/NCT01250938
112	NCT01177969	Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents		Completed	Has Results	Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified	Behavioral: Cognitive-Behavioral Therapy|Behavioral: Wait-list	Pediatric Anxiety Rating Scale.|Anxiety Disorders Interview Schedule: Child and Parent Versions	University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, Los Angeles|University of Miami	All	11 Years to 14 Years   (Child)	Phase 1|Phase 2	33	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	1R34HD065274-01	November 2009	April 2014	April 2014	August 9, 2010	July 1, 2014	July 1, 2014	Univeristy of California at Los Angeles, Los Angeles, California, United States|University of South Florida, St. Petersburg, Florida, United States		https://ClinicalTrials.gov/show/NCT01177969
113	NCT03840642	Examining an Adaptive Telehealth Intervention		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Mirror Me|Behavioral: Remote Coaching	Change in Unstructured Imitation Assessment (UIA)|Change in Early Intervention Parenting Self Efficacy Scale|Change in Parent Fidelity|Change in Vineland Scales of Adaptive Functioning (3rd edition, survey form)|Change in Social Communication Checklist Revised	Rush University Medical Center|University of Chicago|National Institutes of Health (NIH)|Eotvos Lorand University	All	16 Months to 5 Years   (Child)	Not Applicable	61	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	ORA 16122005|KL2TR002387	January 1, 2018	November 1, 2022	February 1, 2023	February 15, 2019		November 21, 2022	Rush University Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03840642
114	NCT02457169	Addressing Systemic Health Disparities in Early Identification and Treatment of Autism Spectrum Disorder (ASD): ABCD Project		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Parent Preschool Engagement intervention|Behavioral: Attention Control	parental school involvement|parent-teacher relationship quality|parent-special education engagement	University of Massachusetts, Boston|Tufts Medical Center|Northeastern University|National Institute of Mental Health (NIMH)	All	14 Months to 3 Years   (Child)	Not Applicable	31	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	UMassBoston|1R01MH104400-01	September 2014	April 2018	April 2018	May 29, 2015		December 4, 2018			https://ClinicalTrials.gov/show/NCT02457169
115	NCT03404505	Effects of a Short-term Parent Mediated Social Training on Developmental Trajectories in Infants	IA	Active, not recruiting	No Results Available	Younger Sibling of Child With Autism Spectrum Disorder|Signs of Developmental Delay|Signs of Communication Delay|Signs of Social Delay	Behavioral: Infant Achievements|Behavioral: Caregiver Education (CE)	Change in parent behavior during the Parent-Child Play Sample|Change in child communication and social engagement sample during the Parent-Child Play Sample|Change in scores on the Mullen Scales of Early Learning Receptive and Expressive Language Raw Scores|Change in scores on the MacArthur-Bates Communication Development Inventory|Change in scores on the CSBS Behavior Sample	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	8 Months to 12 Months   (Child)	Not Applicable	64	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB00065698|R21DC015846	November 3, 2017	November 2023	November 2023	January 19, 2018		December 6, 2022	Kennedy Krieger Institute, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03404505
116	NCT05131659	Intervention-Induced Plasticity of Flexibility and Learning Mechanisms in ASD		Recruiting	No Results Available	Executive Dysfunction|Autism Spectrum Disorder|Adolescent Behavior	Behavioral: Executive function group therapy	Change in Executive Function Challenge Task (EFCT) Scores|Change in Neural Response During Prototype Learning Task Outcomes|Change in Adaptive Behavior Assessment System, Third Edition (ABAS-3) scores	Children's National Research Institute|Georgetown University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	14 Years to 18 Years   (Child, Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00015492|1P50HD105328-01	October 20, 2021	December 31, 2025	May 31, 2026	November 23, 2021		August 31, 2022	Children's National Hospital, Washington, District of Columbia, United States|Georgetown University, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT05131659
117	NCT00080145	RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders		Completed	No Results Available	Child Development Disorders, Pervasive	Drug: Risperidone|Behavioral: Behavior Therapy	Home Situations Questionnaire|Vineland Daily Living Skills Scale|Irritability subscale-Aberrant Behavioral Checklist|Clinical Global Impressions-Improvement (CGI-I)	Yale University|National Institute of Mental Health (NIMH)	All	4 Years to 13 Years   (Child)	Not Applicable	124	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U10MH066764|U10MH066766|U10MH066768|DDTR BD-DD	February 2004	September 2007	September 2007	March 25, 2004		August 16, 2013	Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00080145
118	NCT03388294	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders	PIE	Completed	Has Results	Autism Spectrum Disorder|Neurodevelopmental Disorders	Behavioral: Parents and Infants Engaged	Change in Mean Percent of Parent Child Dyadic Engagement Over Time From Baseline to Posttest 1|Change in Mean Percent of Parent Child Dyadic Engagement Over Time From Baseline to Posttest 2|Change in Rating of Parent Responsiveness to Child Sensory Reactivity Cues From Baseline to Posttest 1|Change in Rating of Parent Responsiveness to Child Sensory Reactivity Cues From Baseline to Posttest 2|Change in Rating of Parent Responsiveness to Child Prelinguistic Communication Cues From Baseline to Posttest 1|Change in Rating of Parent Responsiveness to Child Prelinguistic Communication Cues From Baseline to Posttest 2|Change in Rate of Infant Intentional Communication Over Time, Baseline to Posttest 1|Change in Rate of Infant Intentional Communication Over Time, Baseline to Posttest 2|Change in Respiratory Sinus Arrhythmia From Baseline to Posttest 2 During Social Stimuli|Change in Respiratory Sinus Arrhythmia From Baseline to Posttest 2 During Non-Social Stimuli|Change in Skin Conductance Levels From Baseline to Posttest 2|Change in The Behavioral Observation of Social Communication Change (BOSCC) From Baseline to Posttest 2|Change in The Attention Following Protocol (AF Protocol) From Baseline to Posttest 2|Change in Mullen Scales of Early Learning Receptive Language T-Scores From Baseline to Posttest 2|Change in Mullen Scales of Early Learning Expressive Language T-scores From Baseline to Posttest 2|Change in Sensory Processing Assessment for Young Children From Baseline to Posttest 2 in Hypo-Reactivity|Change in Sensory Processing Assessment for Young Children From Baseline to Posttest 2 in Hyper-Reactivity|Change in The Sensory Experiences Questionnaire Version 2.1 From Baseline to Posttest 1 in Hypo-reactivity|Change in The Sensory Experiences Questionnaire Version 2.1 From Baseline to Posttest 1 in Hyper-reactivity|Change in The Sensory Experiences Questionnaire Version 2.1 From Baseline to Posttest 2 in Hypo-reactivity|Change in The Sensory Experiences Questionnaire Version 2.1 From Baseline to Posttest 2 in Hyper-reactivity	University of North Carolina, Chapel Hill|University of Southern California|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	11 Months to 16 Months   (Child)	Not Applicable	72	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	17-0292|1R21HD091547-01	March 8, 2018	April 1, 2020	May 30, 2021	January 2, 2018	October 29, 2021	October 29, 2021	University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03388294/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03388294
119	NCT03380078	Translating Evidence-based Interventions for ASD: Multi-Level Implementation Strategy	TEAMS	Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Teams Leadership Institute (TLI)|Behavioral: Motivational Enhancement (TIPS for Training)|Behavioral: Classroom Pivotal Response Teaching (CPRT)|Behavioral: An Individualized Mental Health Intervention for ASD (AIM HI)	Provider Training Completion / Certification|Child Improvements on The Eyberg Child Behavior Inventory (ECBI)|Child Improvements on the PDD Behavior Inventory, Parent Extended Version (PDDBI-PX)	University of California, Davis|University of California, San Diego|University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1206	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	990914|R01MH1198101|RO1MH1195001	October 20, 2017	June 30, 2021	May 15, 2022	December 20, 2017		August 3, 2022	University of California, Davis, Sacramento, California, United States|University of California, San Diego, San Diego, California, United States|University of California, Los Angeles, Westwood, California, United States		https://ClinicalTrials.gov/show/NCT03380078
120	NCT03730194	A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders		Completed	No Results Available	Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder|Sleep Disturbance	Dietary Supplement: Melatonin|Behavioral: Bedtime Bank	Actigraphy (total sleep time)|Cleveland Adolescent Sleepiness Questionnaire (CASQ)|Sleep Diary|PROMIS Pediatric Item Bank Sleep Disturbance|PROMIS Pediatric Item Bank Sleep Related Impairment|Dim Light Melatonin Onset (DLMO)|Urinary Melatonin|PROMIS Sleep Disturbance (short form v. 1.0 8b)|PROMIS Sleep Related Impairment (short form v. 1.0 8a)	University of Nebraska|National Institute of Nursing Research (NINR)	All	10 Years to 18 Years   (Child, Adult)	Not Applicable	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	775-18-FB|1K01NR017465-01A1	May 31, 2019	November 1, 2021	November 1, 2021	November 5, 2018		May 19, 2022	University of Nebraska Medical Center, Center for Nursing Science, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT03730194
121	NCT03919721	Field Test of Motivity.Net Software for Data Collection During Behavioral Interventions		Unknown status	No Results Available	Autistic Disorder	Behavioral: Applied Behavioral Analysis	Impact of software on number of updates to programs made by behavior analysts (intervention agility)|Event tracking usability assessed by user ratings|Program editing efficiency as assessed by usage analysis|Impact of software on trial success rate|Impact of software on trials to criterion (number of trials needed to achieve mastery)|Impact of software on total number of targets mastered	Experiad LLC|National Institute of Mental Health (NIMH)|University of Washington|northwest behavioral associates	All	2 Years to 21 Years   (Child, Adult)	Not Applicable	12	Industry|NIH|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	Motivity-II|R44MH098476	November 1, 2019	March 31, 2020	March 31, 2020	April 18, 2019		April 18, 2019	Northwest Behavioral Associates, Bellevue, Washington, United States		https://ClinicalTrials.gov/show/NCT03919721
122	NCT02456298	Comparing Behavioral Assessments Using Telehealth for Children With Autism		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Standard FA+FCT|Behavioral: Pragmatic FA+FCT	Percent Reduction in Problem Behavior	Matthew J O'Brien, PhD, BCBA-D|University of Houston|Emory University|Children's Healthcare of Atlanta|National Institute of Mental Health (NIMH)|University of Iowa	All	18 Months to 83 Months   (Child)	Not Applicable	152	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	IRB#201501781|R01MH104363	June 2015	May 31, 2020	May 31, 2020	May 28, 2015		October 8, 2020	University of Iowa, Iowa City, Iowa, United States		https://ClinicalTrials.gov/show/NCT02456298
123	NCT02445105	Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Autism Navigator Enhanced Practice|Behavioral: Family Engagement plus Autism Navigator	Number of children screened by community service provider|Child age at screening by community service provider|Child age at referral for evaluation by community service provider|Child age at entry into intervention|Child autism symptoms measured with the Autism Diagnostic Observation Schedule|Child developmental level measured with the Mullen Scales of Early Learning|Child adaptive behavior measured with the Vineland Adaptive Behavior Scales|Family measure of resources measured with Family Resource Scale completed by parent|Family measure of stress measured with Parenting Stress Index completed by parent|Family measure of access to community activities measured with Home and Community Activities Survey completed by parent	Florida State University|Emory University|Weill Medical College of Cornell University|Drexel University|National Institute of Mental Health (NIMH)	All	Child, Adult, Older Adult	Not Applicable	10857	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research	MH104423|1R01MH104423-01	December 2015	June 2021	June 2021	May 15, 2015		July 13, 2022	Florida State University, Tallahassee, Florida, United States|Emory University, Atlanta, Georgia, United States|Weill Cornell Medical College, White Plains, New York, United States|Drexel University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02445105
124	NCT00947700	Early Connections, Early Detection and Intervention in Infants at Risk for Autism		Completed	No Results Available	Autism Spectrum Disorder	Behavioral: Assessment, Monitoring & Intervention	Autism Symptoms|Mullen Receptive Language Scale|Communication and Symbolic Behavior Scale|Parent Child Interaction|Parent quality of life	University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)|Autism Speaks|Washington State Department of Social and Health Services|Autism Science Foundation	All	5 Months to 12 Months   (Child)	Not Applicable	100	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	32400|P50HD055782|P30ES007033	January 2008	June 2013	June 2013	July 28, 2009		April 20, 2017	Center on Human Development and Disabilities, University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00947700
125	NCT00698997	Intensive Intervention for Toddlers With Autism (EARLY STEPS)		Completed	Has Results	Autism|Autism Spectrum Disorder	Behavioral: Early Start Denver Model|Behavioral: Standard community care	Language Age Equivalent|Overall Developmental Quotient (DQ)|Adaptive Behavior Age Equivalent Scores|Autism Severity	University of California, Davis|University of Washington|University of Michigan|National Institutes of Health (NIH)|University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	12 Months to 24 Months   (Child)	Not Applicable	118	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	200816233|1R01MH081757	April 2008	July 2013	December 2013	June 17, 2008	February 17, 2020	February 17, 2020	UC Davis Mind Institute, Sacramento, California, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/97/NCT00698997/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT00698997
126	NCT02359084	Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children		Completed	No Results Available	Autism|Developmental Delay Disorders	Behavioral: Family Navigation|Behavioral: Conventional Care Management	Diagnostic interval (Number of days defined as beginning the day of the positive confirmatory screen and ending the day when the family receives a determination (yes/no) of ASD diagnosis)|Time to receipt of ASD services/recommended services|Determination of ASD diagnosis (based on DSM V criteria made by a Board Certified DBP Pediatrician. Assessments are based on site protocols; all use standardized, validated measures appropriate for very young children.)|Satisfaction with Family Navigator (Patient Satisfaction with Interpersonal Relationship with Navigator (PSN-I))	Boston University|Yale University|Children's Hospital of Philadelphia|National Institute of Mental Health (NIMH)|Developmental Behavioral Pediatrics Research Network	All	15 Months to 27 Months   (Child)	Not Applicable	340	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research	H-33008|1R01MH104355	February 2015	August 25, 2021	August 25, 2021	February 9, 2015		January 3, 2022	Yale University School of Medicine, New Haven, Connecticut, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston University School of Public Health, Boston, Massachusetts, United States|South End Community Health Center, Boston, Massachusetts, United States|Dorchester House Multi-Service Center, Boston, Massachusetts, United States|Codman Square Health Center, Boston, Massachusetts, United States|East Boston Neighborhood Health Center, Boston, Massachusetts, United States|MGH Chelsea, Chelsea, Massachusetts, United States|Lowell Community Health Center, Lowell, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02359084
127	NCT00025779	Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders		Completed	No Results Available	Attention Deficit Disorder With Hyperactivity|Autistic Disorder|Pervasive Development Disorders	Drug: methylphenidate|Drug: guanfacine	hyperactivity, impulsiveness, and distractibility	National Institute of Mental Health (NIMH)	All	5 Years to 14 Years   (Child)	Not Applicable	60	NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment	N01 MH70009|N01 MH80011|N01 MH70010|N01 MH70001|DSIR CT	October 2001	November 2003		October 24, 2001		July 28, 2009	UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Yale Child Study Center, New Haven, Connecticut, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00025779
128	NCT00902798	Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder	Perspectives	Completed	No Results Available	Autistic Disorder|Autism Spectrum Disorder|Asperger's Syndrome|Pervasive Developmental Disorder	Behavioral: Cognitive Enhancement Therapy|Behavioral: Enriched Supportive Therapy	Neurocognition|Social cognition|Functional outcome	University of Pittsburgh|National Institute of Mental Health (NIMH)|Autism Speaks|United States Department of Defense|Pennsylvania Department of Health	All	16 Years to 45 Years   (Child, Adult)	Not Applicable	54	Other|NIH|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	MH085851|R33MH085851|R21MH085851|AR100344|05381|2008NF-Autism|ARI2014	August 2010	April 2016	June 2017	May 15, 2009		April 13, 2020	University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00902798
129	NCT05114538	Improving the Part C Early Intervention Service Delivery System for Children With ASD		Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Reciprocal Imitation Training	Child Intentional Communication|Child Initiation of Joint Attention (IJA)|Child Spontaneous Motor Imitation|Parent Contingent Responsivity|Child Elicited Motor Imitation|Child Social Communication|Parenting Self-Efficacy|Family Quality of Life|Parenting Stress|Child Total Word Count	University of Washington|National Institute of Mental Health (NIMH)|Michigan State University|Rush University Medical Center|University of Massachusetts, Boston	All	16 Months to 30 Months   (Child)	Not Applicable	440	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	STUDY00009835|1R01MH122727-01	September 27, 2021	March 2023	March 2023	November 10, 2021		November 22, 2021	Rush University Medical Center, Chicago, Illinois, United States|University of Massachusetts Boston, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT05114538
130	NCT01579669	Partnering With Autistic Adults to Improve Healthcare		Completed	Has Results	Autism Spectrum Disorder	Behavioral: Use of toolkit	Patient Satisfaction|Provider Satisfaction|Patient Use of Toolkit Components|Change in Patient Satisfaction With Healthcare|Change in Patient's Perceived Barriers to Healthcare|Change in Patient Healthcare Self-Efficacy	Oregon Health and Science University|National Institute of Mental Health (NIMH)|Syracuse University|Indiana University|Autistic Self Advocacy Network|Portland State University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	237	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	R34MH092503	September 2013	August 2014	August 2014	April 18, 2012	December 7, 2015	December 7, 2015	Oregon Health and Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT01579669
131	NCT03025646	Feasibility of Implementing a Mental Health Care Program and Home-based Training for Mothers of Children With Autism Spectrum Disorder in an Urban Population in Bangladesh		Recruiting	No Results Available	Maternal Depression	Other: Mental Health care services & home based training	Participants who can accept, afford and adapt the implemented program of mental health service and home based training program|Number of mothers with Major Depressive Disorder (MDD)|Number of children with ASD who have improved their skill in terms of communication, behavior and social skills	International Centre for Diarrhoeal Disease Research, Bangladesh|Harvard Medical School (HMS and HSDM)|National Institute of Mental Health (NIMH)|National Institute of Neurosciences Hospital (NINS)|Institute of Paediatric Neurodisorder and Autism (IPNA)	Female	18 Years to 50 Years   (Adult)	Not Applicable	78	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	PR-16070	April 1, 2017	September 2021	September 2021	January 19, 2017		April 26, 2021	Awf, Swac, Dhaka, Bangladesh		https://ClinicalTrials.gov/show/NCT03025646
132	NCT02839915	Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder		Active, not recruiting	No Results Available	Autism Spectrum Disorder	Drug: Folinic Acid|Other: Placebo	Change in Clinical Evaluation of Language Fundamentals 4 (CELF-4) Score.|Change in Clinical Evaluation of Language Fundamentals Preschool (CELF-P) score|Change in Clinician Global Impression for Improvement (CGI-I) Score	Rossignol Medical Center|Emory University|Harvard University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|State University of New York - Downstate Medical Center|Southwest Autism Research & Resource Center	All	5 Years to 17 Years   (Child)	Phase 2	134	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	FAS-NIH|R01HD088528	August 13, 2020	July 1, 2023	July 1, 2024	July 21, 2016		September 30, 2022	Southwestern Research and Resource Center, Phoenix, Arizona, United States|Children's Healtcare of Atlanta, Atlanta, Georgia, United States|Harvard University, Lexington, Massachusetts, United States|State University of New York, Downstate, Brooklyn, New York, United States		https://ClinicalTrials.gov/show/NCT02839915
133	NCT05565482	Work Chat: An Interactive Virtual Workday		Enrolling by invitation	No Results Available	Autism|Autism Spectrum Disorder	Behavioral: Work Chat: An Interactive Virtual Workday	Change in Social Cognition - Hinting Task|Change in Emotion Recognition Ability - MiniPONs|Change in Emotion Regulation - Emotion Dysregulation Inventory Short Form (Reactivity Index Short Form)|Greater Gains/Change in Workplace Functioning - Workplace Behavior Inventory (WBI)|Greater sustained employment by 9 Months|Change in Social Competence|Change in Perceived Social Self-Efficacy Scale (PSSE)|Change in Perceived Empathy Self-Efficacy Scale (PESE)|Change in Anxiety	University of Michigan|SIMmersion, LLC|Michigan Career and Technical Institute (MCTI)|National Institute of Mental Health (NIMH)|Michigan State University|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Not Applicable	725	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	HUM00216949|R44MH123359-01	October 13, 2022	October 10, 2024	January 10, 2025	October 4, 2022		November 3, 2022	Michigan Career and Technical Institute, Plainwell, Michigan, United States		https://ClinicalTrials.gov/show/NCT05565482
134	NCT00166595	Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)		Completed	No Results Available	Child Development Disorders, Pervasive	Drug: Risperidone		Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	4 Years to 21 Years   (Child, Adult)	Phase 1|Phase 2	100	Other|NIH	Interventional	Primary Purpose: Treatment	PPRU 10545s	February 2003		March 2005	September 14, 2005		January 28, 2014	Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00166595
135	NCT05456139	Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care	ESI-MC	Recruiting	No Results Available	Autism Spectrum Disorder	Behavioral: Treatment as Usual|Behavioral: Early Social Interaction Mobile Coaching (ESI-MC)	Parent-Child Interaction Change at Home|Social Communication Change|Intervention Strategy Use|Observation of Diagnostic Features of Autism Change|Autism Symptoms|Developmental Level|Adaptive Behavior|Brief Observation of Autism Symptoms	Florida State University|National Institute of Mental Health (NIMH)|University of California, Los Angeles|Emory University|Children's Healthcare of Atlanta|University of Pennsylvania|Children's Hospital of Philadelphia|Weill Medical College of Cornell University|Rush University|Seattle Children's Hospital Research Institute|Children's Hospital Medical Center, Cincinnati	All	15 Months to 20 Months   (Child)	Not Applicable	240	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research	STUDY00002656|R01MH121627|R01MH121622|R01MH127120	August 30, 2022	January 2026	January 2026	July 13, 2022		September 1, 2022	University of California Los Angeles, Los Angeles, California, United States|Florida State University Autism Institute, Tallahassee, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Weill Cornell Medical College, White Plains, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT05456139
136	NCT04606966	Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth		Recruiting	No Results Available	Autism Spectrum Disorder|Mental Disorders	Other: Therapeutic Horseback Riding|Other: Barn Activity|Other: Hybrid	Change in Aberrant Behavior Checklist-Community (ABC-C)|Change in Social Responsiveness Scale™, Second Edition|Change in Emotion Dysregulation Inventory (EDI)|Change in World Health Organization's Quality of Life Instrument (WHOQOL-BREF)|Change in Systematic Analysis of Language Transcripts (SALT)|Change in Crisis Mental Health Care Usage Survey	University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Maine Health/Spriing Harbor Hospital|Riding To The Top Therapeutic Riding Center|Hearts and Horses Therapeutic Riding Center|Salimetrics, LLC|Baylor University	All	6 Years to 17 Years   (Child)	Not Applicable	192	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	19-1962|1R01HD097693-01A1	December 22, 2020	June 2024	December 2024	October 28, 2020		October 25, 2022	University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Maine Health, Portland, Maine, United States		https://ClinicalTrials.gov/show/NCT04606966
137	NCT00870727	Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders		Completed	Has Results	Pervasive Developmental Disorder	Drug: Aripiprazole oral product|Drug: Placebo oral capsule	Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2)|Mean Post-baseline Aberrant Behavior Checklist Irritability Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Hyperactivity Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Inappropriate Speech Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Social Withdrawal Subscale Score, Parent Report, Double-blind Phase|Mean Post-baseline Aberrant Behavior Checklist Stereotypy Subscale Score, Parent Report, Double-blind Phase	Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb	All	5 Years to 17 Years   (Child)	Phase 3	33	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	0805-26|MH 082119	February 2009	March 2015	May 2015	March 27, 2009	November 28, 2018	January 2, 2019	Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00870727
138	NCT01233414	Randomized Trial of Parent Training for Young Children With Autism	RUBI	Completed	No Results Available	Child Development Disorders, Pervasive	Behavioral: Parent Training|Other: Psychoeducational Program	Aberrant Behavior Checklist Irritability Subscale|Home Situations Questionnaire|Vineland Adaptive Behavior Scales|Clinical Global Impressions Improvement Scale	Yale University|Emory University|Indiana University|Ohio State University|University of Pittsburgh|University of Rochester|National Institute of Mental Health (NIMH)	All	3 Years to 7 Years   (Child)	Not Applicable	180	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	R01MH081148	September 2010	September 2014	March 2015	November 3, 2010		April 8, 2016	Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Rochester, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01233414
139	NCT01525901	Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)		Completed	Has Results	22q13 Deletion Syndrome|Phelan-McDermid Syndrome	Drug: Insulin-Like Growth Factor-1 (IGF-1)|Drug: Normal saline	Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1|Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2|Change in Repetitive Behavior Scale - Study 2|Change in CGI-Improvement and Severity Scales; - Study 2|Change in Caregiver Strain Questionnaire|Change in Sensory Profile (SP) - Study 2|Change in Short Sensory Profile (SSP) - Study 2	Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)	All	5 Years to 12 Years   (Child)	Phase 2	19	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	GCO 12-0929|IF# 1358648|1R34MH100276-01|GCO 11-1555|R34MH100276	February 2012	August 23, 2016	August 23, 2016	February 3, 2012	May 12, 2022	May 12, 2022	Seaver Austin Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01525901/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01525901
140	NCT03548779	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	NCGENES2	Active, not recruiting	No Results Available	Epilepsy; Seizure|Neuromuscular Diseases|Brain Malformation|Intellectual Disability|Autism Spectrum Disorder|Hypotonia|Inborn Errors of Metabolism|Movement Disorders|Genetic Disease|Development Delay|Chromosome Abnormality|Hearing Loss|Dysmorphic Features|Skeletal Dysplasia|Congenital Abnormality|Microcephaly|Macrocephaly	Behavioral: Pre-visit prep|Diagnostic Test: usual care + exome seq	Number of in-patient hospital admissions 1 year prior to return of results|Number of in-patient hospital admissions 1 year after return of results|Number of in-patient hospital days 1 year prior to return of results|Number of in-patient hospital days 1 year after return of results|Number of long-term care admissions 1 year prior to return of results|Number of long-term care admissions 1 year after return of results|Number of long-term care days 1 year prior to return of results|Number of long-term care days 1 year after return of results|Number of ER visits 1 year prior to return of results|Number of ER visits 1 year after return of results|Number of specialists visits 1 year prior to return of results|Number of specialists visits 1 year after return of results|Initial Patient Pediatric Quality of Life (Peds QL) score|Intermediate Patient Pediatric Quality of Life (Peds QL) score|Final Patient Pediatric Quality of Life (Peds QL) score|Initial Caregiver QoL score|Intermediate Caregiver QoL score|Final Caregiver QoL score|Post-Clinic Visit 1 Mean Patient Centeredness Score|Post-Return of Results Mean Patient Centeredness Score|Number of questions caregiver asks in Clinic Visit 1|Initial Average Peds QL score for "missing school for not feeling well"|Intermediate Average Peds QL score for "missing school for not feeling well"|Final Average Peds QL score for "missing school for not feeling well"|Initial Average Peds QL score for "missing school for doctors visit"|Intermediate Average Peds QL score for "missing school for doctors visit"|Final Average Peds QL score for "missing school for doctors visit"|Initial Amount of work missed because of child's condition or treatments score|Intermediate Amount of work missed because of child's condition or treatments score|Final Amount of work missed because of child's condition or treatments score|Initial Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Intermediate Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Final Difficulty with finishing normal work (including both work outside of the home and housework) because of child's condition or treatments score|Vital status at final f/u|Child causes of death related to the primary condition|Percent concordance of caregiver and provider reports of genetic or genomic test results|Mean Baseline Self Efficacy Score|Mean Pre-Clinic Visit 1 Self Efficacy Score|Post-Return of Results Mean FACToR Uncertainty Subscale Score	University of North Carolina, Chapel Hill|National Human Genome Research Institute (NHGRI)|East Carolina University|Mission Health System, Asheville, NC	All	0 Years and older   (Child, Adult, Older Adult)	Not Applicable	806	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic	17-0816|U01HG006487	September 28, 2018	May 2023	May 2023	June 7, 2018		December 16, 2021	Mission Health, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States	"Informed Consent Form: 7-14 Assent Form 1 Randomization to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_000.pdf|"Informed Consent Form: 7-14 Assent Form 2 Assent to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_001.pdf|"Informed Consent Form: 15-17 Assent Form 1 Randomization to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_002.pdf|"Informed Consent Form: 15-17 Assent Form 2 Assent to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_003.pdf|"Informed Consent Form: Consent Form 1 Randomization to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_004.pdf|"Informed Consent Form: Consent Form 2 Assent to Research", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03548779/ICF_005.pdf	https://ClinicalTrials.gov/show/NCT03548779
141	NCT00205699	Metabolic Effects of Antipsychotics in Children	MEAC	Completed	Has Results	Aggression|Attention Deficit-Hyperactivity|Oppositional Defiant Disorder|Pervasive Development Disorders|Bipolar Disorder	Drug: risperidone|Drug: olanzapine|Drug: aripiprazole	Change in DEXA % Body Fat|Change in Insulin-stimulated Glucose Rate of Disappearance (Glucose Rd)|Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)|Change in Insulin-stimulated Glucose Rate of Appearance (Glucose Ra)|Change in MRI-measured Visceral Abdominal Fat|Change in MRI-measured Subcutaneous Abdominal Fat	Washington University School of Medicine|National Institute of Mental Health (NIMH)	All	6 Years to 18 Years   (Child, Adult)	Phase 4	144	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NIMH|R01MH072912	April 2006	March 2011	July 2011	September 20, 2005	June 15, 2018	June 15, 2018	Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States	"Informed Consent Form: Child and Adult Consent", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_000.pdf|"Informed Consent Form: Genetics Consent", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/ICF_001.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/Prot_002.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/99/NCT00205699/SAP_003.pdf	https://ClinicalTrials.gov/show/NCT00205699
142	NCT00597948	Healthy Lifestyles for People With Intellectual Disabilities	HLID	Completed	No Results Available	Mental Retardation|Developmental Disabilities|Intellectual Disabilities	Behavioral: Healthy Lifestyles Curriculum	Health Promoting Lifestyles Profile II|Body Mass Index (BMI)|waist circumference|Community Integration Questionnaire|Healthy Lifestyles Knowledge Test|Starting and Continuing Healthy Behaviors|Self-Efficacy and Social Support for Activity for Persons with Intellectual Disabilities|Living Well with a Disability Evaluation|General Health Survey|Healthy Lifestyles Goal Tracking Form	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	131	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1R21HD055189-01	April 2007	January 2010	March 2010	January 18, 2008		February 27, 2012	Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT00597948
143	NCT01238575	Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder		Completed	Has Results	Pervasive Development Disorders	Other: placebo|Drug: extended-release guanfacine	Aberrant Behavior Checklist Hyperactivity Subscale|ADHD Rating Scale - Total|Aberrant Behavior Checklist Irritability Subscale|Aberrant Behavior Checklist Social Withdrawal Subscale|Aberrant Behavior Checklist Sterotypy Subscale|Aberrant Behavior Checklist Inappropriate Speech Subscale|ADHD Rating Scale - Inattention Subscale|ADHD Rating Scale - Hyperactivity Subscale	Yale University|Emory University|Massachusetts General Hospital|Seattle Children's Hospital|University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	5 Years to 14 Years   (Child)	Phase 4	62	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1001006172|R01MH083707	December 2011	March 2014	March 2014	November 10, 2010	December 7, 2015	March 31, 2020	University of California, Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01238575
144	NCT03422367	JASPER Early Intervention for Tuberous Sclerosis	JETS	Unknown status	No Results Available	Tuberous Sclerosis	Behavioral: JASPER	ESCS (Early Social Communication Scales) Assessment.|Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine.|Structured Play Assessment (SPA)|SPA|Mullen Scales of Early Learning (MSEL)|Mullen|Social communication	University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Boston Children's Hospital|Massachusetts General Hospital	All	6 Months to 40 Months   (Child)	Not Applicable	64	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB #17-000262|1R01HD090138-01A1	October 24, 2017	June 15, 2022	June 15, 2022	February 5, 2018		November 6, 2020	University of California Los Angeles, Los Angeles, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03422367
145	NCT02991807	RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome		Completed	No Results Available	PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome	Drug: RAD001|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Change in Working Memory at 6 Months|Change in Processing Speed at 6 Months|Change in Fine Motor Skills at 6 Months|Change in Attention at 6 Months|Change in Impulsivity at 6 Months|Change in Global Cognitive Ability at 6 Months|Change in Motor Functioning at 6 Months|Change in Communication Ability at 6 Months	Boston Children's Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Sciences (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	All	5 Years to 45 Years   (Child, Adult)	Phase 1|Phase 2	46	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IRB-P00020332|1U54NS092090	June 12, 2017	February 18, 2021	December 22, 2021	December 14, 2016		February 8, 2022	Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02991807
